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ABSTRACT 
There is an increasing prevalence of cognitive impairment in the rapidly ageing 
population. Cognitive impairment has been shown to be a unique barrier to 
medication adherence in older adults coupled with an increased number of chronic 
conditions and prescription medications. There is a need to identify those who are 
non-adherent in order to reduce the repercussions related to non-adherence such as 
hospitalization and increased health care costs. Although several instruments exist 
to assess adherence, not all can be applied to primary health based setting. 
Pharmacists practicing in novel primary care settings such as Center for Family 
Medicine’s Family Health Team’s Memory clinic measure adherence using pill count 
and pharmacy refill data, however which method is more feasible remains 
unknown. Furthermore, it remains unknown whether the scores obtained using 
these instruments correlate. There is paucity in the current literature that addresses 
the aforementioned gaps. In addition, cognitively impaired older adults require 
assistance in managing medication, however, it remains unclear which adherence 
aids are being used by the caregivers of these patients seen at the memory clinic. 
Therefore, the overall objectives of this thesis were: 1) To map and describe the 
various aspects described in the current literature regarding medication adherence in 
older patients with memory concerns, and, 2) To determine the most feasible method of 
assessing adherence in an interdisciplinary, primary care based memory clinic setting. 
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CHAPTER 1: INTRODUCTION 
 
“The physician must not only be prepared to do what is right himself, but also to make 
the patient, the attendants, and externals cooperate.” –Hippocrates. 1   
 
In recent decades, an immense amount of research has been devoted to the 
development of newer drugs leading to advent of more effective therapies with better 
benefit-to-risk profiles for treating a large number of diseases. This exploration in the 
field of novel drug discovery has led to a shift towards an increased emphasis on health 
outcomes research. 2  Although many of these new treatments have been shown to 
improve health outcomes, an important aspect of patient behaviour is often ignored; a 
patient’s medication-taking behaviour. A patient’s medication-taking behaviour is an 
important component in achieving the intended health outcome (Figure 1). 2   
 
A patient’s medication-taking behaviour is a complex and individual act. The most 
appropriate term that defines this concept is debatable. Several definitions including 
medication compliance, adherence, and concordance are used in the literature 
interchangeably. Although the terms sound synonymous, certain differences exist and it 
is necessary to define each term to clarify these differences.  
Drug therapy  Medication taking behaviour  Health outcome 
 
Figure 1: Importance of medication-taking behaviour 
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1.1 Terminologies 
The most commonly used terminologies are defined below: 
1.1.1 Compliance 
In terms of health care, compliance is defined as: 
 
“The extent to which a person’s behaviour (in terms of taking medications, 
following a diet or executing lifestyle changes) coincides with medical or health 
advice ” 3  
 
The term compliance implies a one-sided role of the health care provider in the 
decision making process and portrays a paternalistic attitude by the prescriber towards the 
patient. Moreover, “non-compliance” suggests refusal to comply or disobedience and 
therefore the term carries a negative connotation. The term concordance was introduced 
to tackle this issue. 3  
1.1.2 Concordance 
Concordance has been defined in medical literature in the following way: 
 
“Concordance is a shared process leading to an agreement between the patient 
and prescriber about the aims of treatments and how these are achieved. The 
process enables the patient to participate fully and to influence the outcome” 4  
 
Although the term implies that patient and the clinician should be equal partners in 
the decision making process, it is not clear how one can identify a patient who desires a 
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participation of this sort. It may also not be possible for all patients to identify the aims of 
treatments which questions the benefits of involving them in the decision making 
process. 3  
1.1.3 Adherence 
Aside from compliance and concordance, adherence is a term that is being 
increasingly used to describe the patient’s act of taking their medications. The World 
Health Organization (WHO) defines adherence as: 
 
“The extent to which a person’s behaviour – taking medication, following a diet 
and/or executing lifestyle changes, corresponds with agreed recommendation 
from a health care provider” 5  
 
This definition emphasizes the importance of a patient-prescriber relationship and 
describes patients’ active collaboration in treatment. The term adherence also offers a 
balance between the responsibility of the prescriber in prescribing a certain therapy and 
the patient’s liberty in accepting a given recommendation. Unlike concordance, this 
definition does not imply that a patient will be able to identify and understands his/her 
condition for a successful treatment. 3  For this reason, the majority of authors in medical 
literature prefer the term adherence to describe patients’ medication-taking behaviour. 
For the purpose of this thesis, the terms adherence and non-adherence were chosen 
because they offer an appropriate relationship balance between the patient choice and 
prescriber authority. Other terms such as persistence and discontinuation represent a 
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different paradigm of medication-taking behaviour. Persistence is the time period 
between the start of a dose to the last dose, which is followed by discontinuation. 6  
1.2 Adherence to medications 
Although medication adherence is known to be an important factor that predicts the 
effectiveness of pharmacotherapy, it is especially crucial for the long-term success of 
medications used in managing chronic conditions. For example, some of the earliest 
research regarding medication adherence indicated that improving adherence to 
antihypertensive treatment improves health outcome by reducing the risk of 
cardiovascular complexities such as myocardial infarction and stroke. 7  Sackett and 
Haynes showed an improvement in blood pressure in their study involving 38 
hypertensive Canadian steelworkers who were non-adherent to their antihypertensive 
treatment. 7  This cohort of participants was divided into a control and intervention group, 
where the intervention group received training on blood pressure monitoring and 
strategies to improve adherence. After a follow up period of six months, the intervention 
group showed a substantial decrease in blood pressure, whereas the control group showed 
only a modest decrease in blood pressure. 7   
Poor adherence has shown to result in increased health care costs and 
hospitalizations. 8  In fact, poor medication adherence contributes to an estimated one-
third to two-thirds of all medication-related hospitalizations in the United States. 9,10  
Furthermore, in 2003, the WHO reported that approximately 50% of patients with 
chronic conditions do not take their medications as prescribed. 5  This medication non-
adherence causes increased morbidity and death, resulting in a total yearly cost of 
approximately $100 billion all over the world. In Canada alone, it was estimated that the 
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cost related to medication non-adherence was in the range of $8 to $10 billion in the year 
2006.11  
1.3 Prevalence of medication non-adherence 
According to the WHO report of 2003, half of the patients suffering from chronic 
conditions are non-adherent to their medications. 5  Although the threshold by which one 
can be considered as non-adherent is debatable, the current consensus among researchers 
indicates that an adherent person will be consuming medications at least 80% of the time 
for most common chronic conditions including hypertension, diabetes and 
hyperlipidemia. 12-14  
The prevalence of medication non-adherence can vary considerably depending on the 
type or duration of the treatment. A number of clinical trials report adherence rates for 
patients suffering from chronic conditions to fall within the range of 43-78%. 14  For 
example, a quantitative review of research on medication adherence over the past 50 
years it is suggested that the adherence rates are lower for conditions like sleep disorder 
(66%) and diabetes (68%), were 50% for heart disease and mental illnesses, and were 
much higher in case of cancer (79%) or HIV treatments (88%). 15    
1.4 Risk factors leading to non-adherence 
It is necessary to understand the causes of decreased adherence in order to improve 
medication adherence. There are several determinants of non-adherence and these causes 
may in turn be multi-factorial. Many review articles on medication adherence, including 
the report by WHO, have broadly classified these factors as patient-related, therapy- 
related, healthcare system-related, socio-economic factor-related and condition-
related.5,16-18  Patient-related factors including patient demographics, low health literacy, 
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lack of involvement in the decision-making process, and poor medication management 
skills are some of the major determinants of non-adherence. 19-21  Therapy-related factors 
are also responsible for lower adherence including patient’s perception of treatment, past 
experiences to therapies and decreased motivation. 22  Factors associated with health care 
system include patient-prescriber relationship, accessibility to health centers, long wait 
times and prior patient experiences during health care appointments. 23  Some of the 
commonly listed socio-economic barriers are treatment cost, lower understanding of 
medication instructions, lack of familial support, and low patient income.17 Lastly, there 
are some key condition-related factors including disease type, severity of disease, and 
impaired cognition, which are also known to cause decreased adherence to 
medications.24,25  
1.5 Assessing medication adherence 
As medication adherence is an individual patient behaviour and can vary among 
individuals, it is challenging to assess adherence. Accurate measurement of adherence 
becomes increasingly difficult due to the absence of a gold standard. A gold standard 
instrument is a tool that has to be inconspicuous (to avoid patient bias and sensitization), 
objective (to produce reproducible results) and practical (to easily incorporate into 
practice with minimal cost). 26   
Broadly speaking, adherence-assessing instruments are categorized as direct and 
indirect methods. Direct measurement instruments take an advantage of detecting specific 
drug related markers or metabolites in blood and urine samples to confirm the 
consumption of medications. 27 Although direct measurement of the drug 
metabolite/marker levels is the most accurate method, its use is often limited due to 
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impracticality and higher costs in routine clinical practice and research. As an alternative, 
there are several indirect tools available to assess adherence. 27 Some of the most 
commonly used indirect methods in the literature include pill counts, 28  pharmacy refill 
dates 29  and structured or semi-structured interviews 30 . The major disadvantages of 
these indirect techniques are that these methods are a proxy measure of patient adherence 
and that they do not guarantee the intake of the drug by the patient. Amongst these 
indirect techniques, the electronic monitoring method is considered to be the closest to a 
gold standard. 28  Electronic monitoring uses a medication event-monitoring system 
(MEMS) equipped with a microchip that records real-time opening and closing of the pill 
container. As with other indirect measuring techniques, the use of MEMS is limited due 
to its inability to measure actual consumption of the medications and furthermore due to 
its higher cost in comparison to other indirect techniques. 27  
1.6 Interventions 
Several adherence-improving interventions have been suggested in the literature. 
These include patient and prescriber education on importance of adherence, collaboration 
between patient and prescriber in the treatment decision-making process, reducing pill 
burden and simplifying treatment regimens by tailoring it to individual patient’s lifestyle, 
use of reminder aids, and support from family members. 31-33  
Although interventional strategies depend on the patient condition and type of 
disease being treated, one of the most impactful strategies shown to improve adherence 
rates is an effective communication between the health care provider and the patient.  
Effective communication between a patient and prescriber involves verbal and non-verbal 
communication, expression of concerns, and participation in decision-making.34 For 
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example, a recent meta-analysis reported an improvement of adherence rate by 19% 
when there was an effective communication between the physician and the patient. 34  
The study has also indicated that an effective communication increased the likelihood of 
patients adhering to their medication by two times. 34  
1.7 Medication Non-adherence in Older Adults: A Public Health Concern 
Over the past 30 years, Canada has seen an increase in the proportion of adults over 
the age of 65 from 10% in 1984 to 16% in 2014. 35  Lower birthrates and longer life 
expectancy will continue to trend the aging population upwards, with estimates reaching 
28% of the total population by 2063.  The upward trend in an aging population is 
concerning, as the presence of chronic conditions increases with age. In 2009 it was 
reported that 89% of adults over the age of 65 had at least one chronic condition, and 
older adults are four times more likely to report having a chronic condition compared to 
the 18-24 year old population. 36 The chronic conditions most associated with aging are 
osteoarthritis, osteoporosis, cardiovascular diseases, cancer, diabetes, Alzheimer’s 
disease and other dementias. 36  Older adults also face an increased number of co-chronic 
conditions, for example, 25% of Canadians aged 65 to 79 years and 37% of those aged 80 
years and older reported having four or more chronic conditions. 37   
Closely related to multiple chronic conditions is an increase in the number of 
prescription medications among seniors. 38  On an average, seniors took three to four 
prescription medications when they reported one or two chronic conditions and six 
prescription medications when they reported three or more chronic conditions. 38  Self-
managing such a large number of medications often becomes challenging to older adults 
with many noted barriers to chronic disease management including comorbidity and 
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functional disability. 39  Difficulties with self-managing medications and/or the resulting 
therapeutic regimens ultimately affect an older patient’s medication-taking behavior and 
is commonly known to lead to non-adherence. 40  This non-adherence to medications is a 
cause of increasing hospitalization among older adults. In fact, drug non-adherence 
attributes to an estimated 10% of total hospitalizations worldwide.  
Among the many risks associated with co-morbidities faced by older adults such as 
the consequences of frailty, an increased risk of memory impairment with increasing age 
also raises concern. The prevalence of cognitive impairment is on the rise with the rising 
ageing population. This increased prevalence of cognition-related disorders such as mild 
cognitive impairment, dementia, and Alzheimer’s disease further impacts the ability of 
older adults to carry out their daily activities including managing their medications. This 
further adds to the risk of non-adherence in this population. In addition, the behavioural 
and psychological symptoms of dementia (BPSD) increase the burden on the caregiver of 
the patient, leading to increased caregiver stress and reduced support for these patients. 
All these factors have been associated with reduced medication non-adherence, making 
managing medications and adherence a huge challenge in this population. However, most 
of these factors that may affect adherence in this population are under studied or have not 
been studied extensively.  
In the recent years, a novel approach has been developed and adopted in Southern 
Ontario to help manage the conditions of older adults with memory concerns. The first 
clinic dealing with patients in a primary health care setting was established in 2006 at the 
Center for Family Medicine in Kitchener. This model has since spread to various other 
cities in Ontario such as Cambridge, London, and Ottawa. These novel practice sites are 
 10 
commonly known as “memory clinics". These memory clinics are comprised of an inter-
disciplinary team consisting of a physician, nurse, pharmacist, social worker and 
occupational therapist. This team aims to manage several aspects of memory impairment, 
including the health aspect, therapy aspect, and social aspect. The memory clinic model 
was developed with the aim to support older adults with memory concerns progressing 
towards dementia and Alzheimer’s disease. The team focuses on slowing the progression 
by eliminating some of the risk factors associated with dementing illnesses. In particular, 
the pharmacist plays a key role in the therapy related aspect of managing the problems 
related to older adults. This includes the addition or elimination of drugs from the current 
therapy in order to manage the underlying conditions, and assessing and improving 
adherence to medications. An important barrier to assessing adherence is the lack of a 
gold standard. This stands true in memory clinic setting as with other research studies. 
13,14,27,41  As previously mentioned, there are two major assessment techniques for 
clinicians to choose from, direct and indirect methods. The use of direct methods is not 
possible in general practice mainly due to cost and feasibility among other disadvantages. 
Indirect methods provide a clinician the flexibility to assess adherence without worrying 
about the cost. Specifically in a memory clinic setting, the pharmacist uses pharmacy 
refill history and pill count to assess adherence. However, performing both of these 
methods on all patients can be time-consuming and laborious for the pharmacist, as 
he/she has other duties entitled to perform. Hence, there is a lack of studies showing the 
most feasible method among the two in a clinical setting.  
To address the aforementioned gaps in the current literature, the overall objectives of 
this thesis are: 
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1. To map and describe the various aspects described in the current literature 
regarding medication adherence in older patients with memory concerns, and, 
2. To determine the most feasible method of assessing adherence in an 
interdisciplinary, primary care based memory clinic setting. 
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CHAPTER 2: A SCOPING REVIEW ON MEDICATION 
ADHERENCE IN OLDER ADULTS WITH MEMORY 
CONCERNS 
2.1. Background 
Patient adherence is of utmost importance for optimal effectiveness of prescribed 
medications. 17  Failure to adhere to a prescribed medication regimen can lead to 
suboptimal clinical outcomes. Previous research has indicated that poor adherence to 
beta-blockers was associated with a 4.5 times increased risk of coronary heart disease in 
patients with hypertension compared to those whose adherence was 80% or greater.  42  
Patient behaviours related to adherence are dynamic, vary according to disease states, and 
are subject to multiple interacting factors such as the number of medications and 
complexity of prescribed regimens.  14  It becomes more challenging for patients to adhere 
to their prescribed medications when medication regimens increase in their complexity. 
For example, the mean adherence in a cohort of older adults was 37%, and was inversely 
associated with complex drug regimens [Odds ratio (OR)= 7.4, 95% Confidence Interval 
(CI) 3.2, 16.9].  43  Moreover, many older adults consume multiple medications, yet they 
appear to have adherence estimates that are higher, lower, or comparable to that of 
younger adults. 17  Nevertheless, this population presents a unique challenge with regards 
to optimal medication adherence due to the frequency of polypharmacy coupled with the 
requirement of following a complex set of medication taking instructions. Increased 
concerns about medications, greater number of chronic medications, higher cost, 
 13 
decreased mobility and lack of satisfaction with care represents additional barriers that 
negatively impact medication adherence in older adults. 44  
Cognitive impairment is an important barrier to adherence in older adults over the age 
of 65 years. The current prevalence of cognitive impairment (includes mild cognitive 
impairment and Alzheimer’s Disease and Related disorders) in Canada is 8% in the age 
group of 65-74 years old, which increases dramatically to 28-61% among those aged 75+ 
years. 45  Cognitive impairment has also been shown to have negative effects on 
medication adherence. 46  Patients dealing with cognitive impairment have difficulty 
remembering to take medications as adherence to medication regimens requires a set of 
complex cognitive skills such as accessing medications, understanding directions, and 
scheduling medication taking times. 47  The aforementioned tasks require verbal memory, 
working memory, processing speed and reasoning, some or all of which would be 
expected to be impaired in patients with cognitive impairment. 47  A major consequence 
of dementing illnesses is that special attention is required with regards to appropriate 
medication use, including optimizing adherence. 48   
Accurate estimation of medication adherence is important to determine the success of 
an intervention to improve adherence or to account for effectiveness of a drug regimen. 27  
A major challenge in this regard is the lack of a gold standard measure of adherence. A 
gold standard is an ideal tool or method, which is simple, valid and reliable, with an 
optimal balance of sensitivity and specificity for assessing medication adherence. 27  
While numerous methods are available to assess adherence in older people, they are all 
fraught with limitations. 17,27  
Unfortunately, there is a dearth of information regarding various aspects of 
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medication adherence in people with cognitive impairment, such as the prevalence of 
non-adherence, barriers associated with non-adherence, adherence enhancing methods 
used by patients, and effectiveness of available interventions aimed at improving 
adherence. The objective of the scoping review was therefore conducted to map the 
current literature, to address gaps in the literature, to examine the extent and range of 
research activity, and finally, to summarize the research findings. 
2.2. Methodological framework 
The Arksey and O’Malley’s framework for scoping reviews was used for the present 
study. 49  The following steps were thus undertaken: (1) development of research 
question, (2) location of relevant publications, (3) screening and selection of publications, 
(4) data charting, and (5) data analysis and summary of the results. Lavec et. al refer to 
scoping studies as “mapping”, which is a process of summarizing a range of evidence in 
order to convey the breadth and depth of a field. 50  Mapping may act as a blueprint to 
examine the extent, range and nature of research activity, determine the value of 
undertaking a full systematic review, summarize and disseminate research findings, or 
identify research gaps in the existing literature. 51   
2.2.1. Step 1: Development of research question 
This scoping review focused on mapping the area of medication adherence in patients 
with cognitive impairment. The research question was “What is known about medication 
adherence in patients with cognitive impairment?” The focus of this review is on 
medication adherence in cognitively impaired patients. The working definition for 
adherence has been given in Chapter 1. Our specific research questions were: 
a) What is the prevalence of non-adherence in patients with cognitive impairment? 
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b) What are the most common methods used to assess adherence in cognitively 
impaired patients? 
c) What are the barriers to adherence in this population? 
d) What interventions are available to improve medication adherence in patients with 
cognitive impairment? 
e) What is the efficacy of methods identified in d) in improving medication 
adherence in patients with cognitive impairment  
2.2.2. Step 2: Location of relevant publications 
In keeping with the methods used for this review, the search strategy was 
designed to be sufficiently broad in order to decrease the chance of missing key articles. 
The search strategy was developed in collaboration with the author’s supervisor (CF) and 
a medical librarian (SG). A comprehensive search of electronic databases including 
Pubmed, MEDLINE (Ovid), EMBASE, CINAHL, IPA and Pyschinfo was conducted 
during the time period of 1966 to January 2015. Search terms were as follows: 
(medication adherence, medication non-adherence, medication compliance, medication 
non-compliance, medication persistence, drug adherence) AND (dementia, alzheimer, 
lewy body, lewy bodies, vascular, mixed, cognitive impairment )AND (assess*, measur*, 
evaluat*).  
2.2.3. Step 3: Screening and selection of publications 
Two investigators (ZH and CF) screened the titles and abstracts independently 
with 98.6% inter-reviewer agreement. The publications were reviewed by reading the 
titles and abstracts of the citations. Studies were included if they examined medication 
adherence and/or compliance in patients with Alzheimer’s disease or related disorders. 
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All selected studies were included regardless of publication date or language. After 
screening the titles and abstracts for inclusion, the selected studies deemed eligible for 
inclusion were read. The disagreements on inclusion/exclusion of studies between the 
authors were resolved by discussion.  
Studies that dealt with persistence and/or discontinuation were excluded, as the 
working definition for the purpose of this review was adherence. Moreover, studies were 
excluded when English translation was unavailable (7 articles: 4 Spanish, 2 Japanese & 1 
German). In addition, one study was later excluded as it only addressed the complexity of 
drug regimens and cognitive impairment (Figure 2).  
2.2.4. Step 4: Data charting 
As per Arksey and O’Malley’s framework, each publication was categorized 
based on the authors, publication year, title of the publications, country (based on the 
location of the first author), study design, outcome variable, methods used to assess 
medication adherence, objectives and key findings. 49  
2.2.5. Step 5: Collating, summarizing, and reporting the results 
This phase was carried out in three distinct steps. First, the data was extracted based 
on the general characteristics of the studies, i.e. the publication date, the country (based 
on the location of the first author), and the adherence assessment methods employed. 
Second, the results were summarized based on the research question and specific 
objectives. Thus, the information on prevalence (objective 1), methods to assess 
adherence (objective 2), barriers (objective 3) and interventions (objective 4&5) was 
summarized. The results were categorized and described based on the specific objectives. 
Finally, the clinical and research implications were described. 
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2.3. Results 
The initial search of electronic databases yielded 581 citations, of which 535 
remained after removing 46 duplicates (Figure 2). The search strategies for each database 
and their remits can be found in Appendix 1. After reading through each title of the 535 
citations, 112 abstracts were selected for screening purposes. After screening these 
abstracts, 60 full-text studies were reviewed and assessed for eligibility. A total of 42 
studies and 2 conference proceedings were deemed eligible for this review. 
The publication dates of the papers that were selected for this review are shown in 
figure (2). A large number (n=27) of studies were published in the last five years and 
more than half of the research emanated from the United States (n=23).  
2.3.1. Prevalence of medication non-adherence in cognitively impaired older adults 
Medication non-adherence appears to be common among patients with ADRD, 
ranging from 2% to 69.9% and varies based on the method used to assess 
adherence.13,21,23,46,48,52-66  For example, using self-reported and/or caregiver reported 
adherence, non-adherence ranged from 2% to 59%. 21,23,46,55,62,63,66  By comparison, the 
proportion of non-adherent patients as assessed by electronic monitoring, refill data, and 
by pill count ranged from 32% to 48.5%, 13,52,53,65,67  19.3 to 66.1% 48,54,56,57,59-61  and 
15.7% to 26.5%, respectively. 48,53,58,64  The variability in these estimates limits our ability 
to make cross study comparisons. 
2.3.2. Methods to assess medication adherence and their limitations 
The most commonly used methods to assess medication adherence included self-
reported adherence (32%), Pharmacy refill and claims data (27%), Pill count (14%), 
health provider’s report (14%), electronic monitoring (10%) and clinical health outcomes 
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(3%). 13,21,23,46,48,52-66  No direct methods were used in any of the identified studies (Table 
1).   
Self-report measures utilized standardized questionnaires and structured 
interviews to assess adherence.21,23,46,55,62,63,66 Boada and Arranz 55  used a standardized 
questionnaire called the Morisky scale, while others relied on structured interviews for 
patients and their caregivers. 21,46,55,62,63,66 Morisky scale is a 4-item self report scale 
which include questions such as “Do you forget to take your medications?”, “Are you 
careless about your medications?”, “When you feel better, do you sometimes stop ta king 
your medications?” and “Sometimes if you feel worse when you are on medications, do 
you stop taking them?”. Reported advantages of self-report methods include ease of 
administration, but these measures are prone to social desirability bias, recall bias, and 
error in self-observation, all of which may lead to patients over estimating their degree of 
adherence. 27  
Pharmacy refill data was the second most commonly used method to assess 
adherence (27% of studies). 48,54,56,57,59-61  This method was reported as an alternative 
medication adherence assessment method in primary care based clinical settings when 
pill count was not available. 68  Based on pharmacy refill data, medication adherence was 
measured using the medication possession ratio. Medication Possession Ratio (MPR) was 
defined as the ratio of total days’ supply of medication to the number of days that the 
patient should have been taking the medication. An MPR value greater than 0.80% was 
considered as ‘adequate’ adherence in all studies included in this review; thus this value 
was used as a dichotomous cut-off between adherent and non-adherent patients.  69  The 
reported shortcomings of this method include that it does not guarantee the administration 
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of the medications, nor does reflect the timing of drug consumption. This method might 
limit assessment of medication adherence in cases were patient were accessing different 
pharmacies to refill their medications. 27,53,69   
The third most commonly used method (14%) was pill counts.  48,53,58,64  Pill count 
has been reported to be one of the simplest methods to assess adherence. A pill count is 
performed by counting the pills present in the medication container, then multiplying by 
the dosage and then dividing the resulting number by the number of pills that should have 
been consumed as per prescribed dosage and number of days within the analyzed period. 
(No. of pills dispensed – No. of pills in the container/No. of pills that should have been 
taken during the given time period) Pill counts have been suggested as an approach that is 
not subject to recall or social desirability bias and was found to be a method of choice in 
clinical and research settings. 27,68  The disadvantage of pill count methods is that they do 
not guarantee consumption of the medication nor do they reflect the exact timing of 
medication consumption. 27   
Some studies utilized electronic monitoring methods to assess adherence 
(10%).13,52,53,65,67  MedTrackerTM pillboxes and the Medication Event Monitoring 
Systems (MEMS) are devices which were used in the included studies. 13,52  These 
devices are equipped with microprocessors on the lids, which record the times of every 
lid opening.52  Electronic monitoring has been regarded by some as the closest ‘gold 
standard’ because it allows researchers to measure adherence in ‘real time’, yet 
medication consumption is assumed, not verified, and cost is an important limitation.67  
In addition, use of such devices has been deemed impractical for health care providers in 
daily practice.27  To date, only one study has compared MEMS with other measures such 
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as pill count, clinical rating scales of compliance and self-report. 53  A weak to moderate 
correlation between these measures was observed with Kappa correlation ranging from 
0.256 to 0.382.  53  
2.3.3. Barriers to medication adherence 
A number of barriers were identified that might contribute to non-adherence in 
cognitively impaired individuals. These factors were broadly classified in relation to 
patient, medical conditions, therapy, socioeconomic, and health system barriers (Table 2).   
 
Patient related barriers 
Patient factors associated with non-adherence include problem drinking, 46  non-
Caucasian race,  61  younger age,  60  and female gender.  53,60  For example, in an ad hoc 
study involving older patients from 11 countries, problem drinking was significantly 
associated with medication non-adherence [OR= 3.6, 95% CI (1.08, 7.16)].  46  Non-
Caucasian race has also been associated with non-adherence. For example, being 
Hispanic was associated with lower adherence rates than whites for Dihydropyridine 
Calcium Channel Blockers (CCBs) [OR= 0.69 95% CI (0.53, 0.89)] and Cholinesterase 
Inhibitors (ChEI) [OR= 0.77 CI(0.61, 0.96)]. 61  On the contrary, other patient related 
factors such as age, and male gender have been associated positively with medication 
adherence. In a study showed involving patients on Alzheimer’s Disease (AD) 
medications, patients >86 years were likely to be more adherent as compared to patients 
on the same medications who were  <75 years of age (OR= 1.401, p<0.001). 60  This 
study also showed that male gender was more likely to be adherent to AD medications as 
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compared to female gender (OR= 1.175, p<0.05) 60 . Kim also documented a similar 
association between female gender and adherence. 53  
 
Barriers related to medical conditions 
Medical conditions-related factors include having good physical health, reduced 
attention, 23  reduced executive function, 70  dementia, and cognitive impairment, with the 
latter 23,46,59,70  being cited as a key factor associated with medication non-adherence. 17  
Indeed, the relative risk of non-adherence increased four times in patients with low 
cognitive function (Mini Mental State Exam (MMSE) score<23) as compared to patients 
with high cognitive function (MMSE≥23)  [RR= 4.1, 95% CI (3.47, 4.78)]. 52  Similar 
studies showed that cognitively impaired individuals were at higher risk of non-
adherence as compared to those who are cognitively intact [Adjusted RR= 2.0, 95% CI 
(1.4, 2.8)]. 71  
In addition to cognitive impairment, dementia is also associated with non-
adherence. 59 ,  23 ,  70  For example, in a cross sectional study that included older persons 
living in their homes, it was found that non-adherence was significantly associated with 
the probability of having dementia [OR= 9.0, 95% CI (1.1, 72.5)].  23  Similar associations 
were noted in another study where adherence to anti-hypertensive medication was 
inversely associated with those having psychiatric disorders accompanied by functional 
impairment such as AD [adjusted OR= 0.865, 95% CI (0.791, 0.945)] and vascular 
dementia [adjusted OR= 0.785 95% CI (0.672, 0.917)]. 59   
Some studies (n=7) identified medication management as a challenge for 
cognitively impaired individuals. Park et al., noted that managing medications require 
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components of complex cognition skill sets such as comprehension, working memory, 
long-term memory, prospective memory and reasoning, thus suggesting that adhering to 
complex medication regimens might be a challenge for cognitively impaired patients. 47  
This set of complex cognitive skills is required for medication management and have 
been associated with medication adherence, for example poor treatment adherence in 
older adults with heart failure was associated with reduced performance on attention 
executive function, and language.  25  Furthermore, the ability to take medications 
correctly was positively correlated with a high MMSE score.  72  In contrast, another 
study showed this correlation to be non-significant. The participants with incorrect Clock 
Drawing Test (CDT) on MMSE had one or more medication discrepancies as compared 
to those with accurate CDT (68% vs. 48%, c2 = 2.64, df =1, p=0.044).  73  Other practical 
problems that hamper medication management and drug taking in CI population were 
difficulties with vision (32.0%), blister opening (12.1%), tablet swallowing (14.8%), 
tablet splitting (29.7%) and distinction between different drug packages (23.4%). 21  A 
Canadian qualitative study found that medication management varied at different stages 
of dementia. For example, independent management, denial of disease and unwillingness 
to take medications owing to anger, characterized medication management in patients 
during the early stages of dementia. Those at a later stage refused to take medications due 
to delusional thinking or suspicions about the medications. 74  
 
Heath care system related barriers  
Health care system barriers associated with medication non-adherence include 
having poor communication between patient and health care provider, 23  obtaining 
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prescriptions from more than one physician/prescriber 23  and having one previous 
occurrence of medication non-adherence.  66  Poor communication between a patient and 
a health care provider often leads to non-adherence. For example, Barat et al. found a 
disagreement between drug information regarding doses (in 71% of the population), 
regimens (in 66% of the population) and drugs (in 22% of the population) collected from 
non-adherent participants and physicians. 23  Furthermore, the odds of being non-adherent 
to medications was 2.5 times greater in those patients who had prescriptions from more 
than one physician [OR= 2.5, 95% CI (1.1, 3.5)]. 23  In a prospective study by 
Thirucheselvam et al., the odds of non-adherence was 2.5 times higher in those patients 
who have had at least one previous occurrence of medication non-adherence in the past 
[OR = 2.61; 95% CI (1.18-5.62)]. 66  
 
Socio-economic related barriers 
Socio-economic barriers that were found to be associated with medication non-
adherence include high medication costs,  75  poor social support  46,48,70,71,76  and caregiver 
stress.  76  A retrospective study was performed on 6990 AD patients to evaluate the 
impact of patient’s AD medication cost-share on adherence to chronic medications 
including adrenergic blockers, antiplatelets, antidiabetics and diuretics. AD medication 
cost-share was defined as the patient’s out-of-pocket (OOP) prescription costs. This OOP 
costs depended on the characteristic of their health plan and formulary status of the AD 
medications. The study reported that AD patients with high out-of-pocket cost [> 
Canadian Dollar (CAD) 24.69] had significantly worse adherence to diuretics and beta-
adrenergic blockers (p<0.05) than those with low OOP costs [< CAD6.38]. 75   
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Lack of social support in patients with ADRD was also correlated to medication 
non-adherence. For example, a study that included patients from 11 countries 
demonstrated that being unmarried was inversely associated with medication adherence 
[OR= 2.323, 95% CI (1.089, 4.956)].  46  There was also an increased risk of non-
adherence in patients who lived alone versus those who did not [OR= 2.9, 95% CI (1.2, 
7.5)]. 71  Foebel et al. found that having a caregiver at the same residence reduced the 
likelihood of medication non-adherence in patients with mild cognitive impairment 
(MCI). 76  In many cases, however, the caregiver is the spouse of that patient who may or 
may not be cognitively intact, which may also negatively impact medication adherence. 
Indeed, this was observed in a study in which patients with dementia patients with 
cognitively impaired spouses experienced difficulty complying to medication regimens 
compared to those with cognitively intact spouses. 48  
 
Therapy related barriers 
A therapy related barrier associated with non-adherence include the increased pill 
burden: 23,66  among a random sample of 348 patients aged 75 years, 4% of which had 
dementia, the use of three or more drugs was found to have a negative impact on 
medication adherence [OR (for non-adherence)=2.5; 95% CI (1.5,4.1)]. 23 These results 
were consistent with another study of 339 cognitively impaired older patients who lived 
alone in which a positive association between non-adherence and taking four or more 
medications [OR=2.58, 95% CI (1.3-5.29)] was observed. 66   
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2.3.4. Interventions 
Several studies (n=10) have reported interventions to improve medication 
adherence in cognitively impaired adults (Table 3). For the purpose of this review, these 
interventions are categorized into alternative dosage forms, multi-compartment pillboxes, 
and medication reminder aids.  
 
Alternate dosage forms 
Alternative dosage forms that have shown improvement in medication adherence 
include transdermal patches 55,77-79  and once–daily, higher–dose oral drug products. 79-81  
Rivastigmine transdermal patches were proved clinically effective in improving the 
condition of patients with probable AD.44 An open label evaluation of patients treated 
with rivastigmine patches showed a modest improvement of MMSE scores after 24-
weeks, during screening (19.6 points) and at week 24 (20.9 point). 77  Rivastigmine 
patches have shown stabilization in adherence scores. For instance, more patients treated 
with transdermal patches were adherent versus those treated with capsules (65.0 vs. 
41.4%, p=0.001). 55  In addition, caregivers of patients with AD were more satisfied with 
rivastigmine transdermal patches versus capsules (72% vs 65% (p=0.001). 55  Blesa et al. 
also found that 72% of caregivers of AD patients preferred rivastigmine patches to the 
capsule. The reported reasons for preference of patches over capsules were ease of use, 
ease of following the dosing schedule and less interference with daily life. 78  Once daily 
and higher-dose memantine extended release formulation (ER) (28mg) and Gingko 
biloba products may also improve treatment adherence by simplifying the drug regimen 
for both caregivers and patients with AD. 80,81  For example, Czeche et al. found that 
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patients receiving Gingko biloba 240mg once daily were at lower risk for non-persistence 
than those receiving 120mg twice daily [Hazard Ratio (HR) = 0.63; 95% CI (0.57, 0.70)]. 
80   
 
Multi-compartment pillboxes and packaging 
The use of multi-compartment packaging has been shown to have positive effects 
on medication adherence. A study conducted by Kakkad et al. found that Calendar Blister 
Packaging (CBP) was associated with 10% higher MPR rates for antihypertensive 
medications compared to vial use in dementia patients. 82  Furthermore, a study assessed 
the ease of use of various Multi-compartment Medication Devices (MMD) (e.g., 
VenalinkTM, Nomad ClearTM and Dosette MMDs) in cognitively impaired and 
cognitively intact individuals. Findings demonstrated that cognitively impaired 
participants had more difficulty in opening VenalinkTM and removing medications from 
NomadTM as compared to cognitively intact participants. 83  In comparison to NomadTM 
and VenalinkTM, Dosette MMD received the best overall rating by 54% of the 
participants.  
 
Medication reminder aids 
Individualizing memory cues has shown to improve adherence in cognitively 
impaired patients. For example, Insel et al. demonstrated that an intervention using 
individually tailored memory cues, such as placing medicines in an area routinely used 
(e.g., dining table, bathroom) by an individual could increase medication adherence. 65  
Specifically medication adherence of 27 older adults (including cognitively impaired 
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older adults) was electronically monitored for 8 weeks pre-intervention and 8 weeks post-
intervention. The number of correct doses taken increased from 64.5% to 78% by the end 
of the study period. 65  Medication reminder devices have also been associated with an 
increase in medication adherence in patients with MCI. 84  For example, a pilot study was 
conducted to evaluate the use of an automatic pill dispenser involving 18 cognitively 
impaired participants. One month after the onset of automatic pill dispenser use, 55.5% 
(n=10) users showed 100% improvement in adherence scores and 49.9% (n=9) 
maintained the score until the end of the study (after three months). 84  Although the study 
revealed that such devices could improve adherence in CI patients, further research is 
needed in order to validate the results from the pilot study. 
2.4. Discussion 
Over the past five years, an increased number of studies have assessed medication 
adherence among older adults living with cognitive impairment. A large number of these 
studies emanate from the United States and Europe. As the chances of cognitive 
impairment increase with age, and because these geographical areas habituate a large 
aging population, it may explain why many research studies are conducted in the west, 
including the United States and Europe. Prevalence estimates of non-adherence range 
from as low as 2% to as high as 69.9% in this population, and as there is no gold standard 
to assess medication adherence, these findings are not surprising. Each adherence 
assessment method has advantages and disadvantages. The most commonly used 
assessment method of self-report is easy to administer in a clinical setting, but is subject 
to a number of biases, such as social desirability and recall bias. Conversely, electronic 
monitoring using MEMS supplies a wealth of adherence data but is difficult to administer 
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in a clinical setting due to its cost. Alternative techniques such as the use of pill count and 
refill history data are becoming popular methods of choice in primary care clinic settings 
due to their ease of use and comparably lesser number of biases. These approaches are 
especially important in settings such as memory clinics, where assessment of medication 
adherence is part of practice. However, both of these methods do not guarantee the 
consumption of medications by patients, thereby making it difficult to assess whether 
patients are actually taking their medications as prescribed. Furthermore, in a study 
comparing various adherence assessment methods, it was found that there was a poor 
correlation between these methods.23  
Other objectives of this review were to describe the barriers related to non-adherence 
and the interventions available to improve adherence in patients with cognitive 
impairment. In this review, the barriers were categorized into patient related, condition 
related, health care system related, therapy related and socio-economic related. Some of 
the barriers that are unique to this population include difficulty in managing medications, 
reduced cognitive skills and cognitive impairment, presence of dementing illnesses, 
increased caregiver stress, and presence of a cognitively impaired spouse. 23,25,46,47,48,59,70-
72,76 Some studies described strategies to deal with these barriers and to improve 
adherence. Interventions have included the use of alternate dosage forms such as a 
transdermal patch and once-daily higher dose oral products, multi-compartment devices 
such as CBP, and medication reminder aids.50,65,77-84 Transdermal patches and once-daily  
higher dose drug products have shown to improve adherence by simplifying the 
medication regimen for  patients and their caregivers. Multi-compartment devices have 
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also shown to be positively associated in improving adherence, but cognitively impaired 
older adults face difficulty in using such devices. 
To our knowledge, this scoping review is the first that encompasses all aspects of 
medication adherence. We assessed medication adherence in a broader context, addressed 
medication adherence assessment methods in more detail, at all aspects of adherence and 
presented an updated literature review on this topic. While other reviews are available on 
this topic 16,17 only one systematic, evidence-based review was conducted specific in 
older adults with dementia. 18  The barriers reported by Campbell et al included difficulty 
in managing medication and in understanding directions, taking four or more 
medications, prior history of non-adherence, a caregiver with dementia, and increased 
overall pill burden. 16  They also reported interventions that attempted to improve 
adherence in dementia patients. These interventions include the use of reminder cues and 
organization boxes, and tele-video medication reminders. 18  This review highlighted that 
barriers to adherence other than impaired cognition should be addressed with equal 
importance. 18  
Although there is an increase in the number of studies pertaining to this population, 
there are several gaps in the literature that need to be addressed. One of the major 
difficulties in comparing studies is the large variation in adherence estimates. As there is 
no gold standard method to assess medication adherence across all populations, which 
makes it difficult to compare data across studies. A standard method to assess medication 
adherence that is reproducible and reliable across all populations is needed to better 
understand and compare data obtained from future studies. Second, assessing medication 
adherence for these patients is part of practice at many primary care settings. Due to the 
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number of assessment tools available, it is unknown which method is most feasible that 
can be applied to a memory clinic setting. A single feasible tool is necessary to allow 
health care providers to identify adherence patterns in this population, thereby helping 
them to work collaboratively to develop patient-specific solutions to tackle suboptimal 
medication adherence. Third, it has been identified that adherence can be affected by 
cognitively impaired spouses or caregivers. 48  Spouses of patients are generally in the 
same age group where there is an increased prevalence of cognitive impairment, and they 
are therefore also at risk for non-adherence. Unfortunately, there is a dearth of 
information on how to address adherence issues in cases where both patient and care 
giver have cognitive impairment. 
Lastly, some interventions to improve adherence in cognitively impaired patients 
have been described. For example, use of rivastigmine transdermal patches and once-
daily oral memantine formulations have shown promising results, and have shown to 
significantly improve adherence to AD medications as compared to capsules. 77,78  Both 
these interventions have shown to simplify the therapeutic regimen and improve 
medication adherence. Transdermal patches are not available for all prescription 
medications; therefore, making this strategy of limited utility given that older adults 
consume an average of seven chronic medications. An alternative to the use of 
transdermal patches could be the use of extended released oral products or use of once 
daily dosing wherever possible, as Czeche et al have shown significant improvement in 
adherence to once-daily extended release Memantine and Gingko biloba products. 80  
Future studies should aim at studying other extended release chronic medications and its 
effect on adherence in cognitively impaired patients. Other interventions such as the use 
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of automated pill dispensers and multi-compartment pill-boxes are available and have 
been studied in the current population, yet, it is unlikely that the issue of medication 
adherence among patients with cognitive impairment will be satisfactorily addressed by 
such devices because patients are dependent on their caregivers to set up and operate 
these devices.  
2.5. Limitations of the review 
This review has several limitations that should be noted. There is a possibility that 
some studies with negative results were not published leading to publication bias. To 
minimize the chance of missing key articles, all online databases were searched for 
eligible studies and no restriction on the dates was applied during the search. Although 
the search strategy was not restricted to the English language, some studies had to be 
excluded, as English translation for these articles was not available. The quantity of data 
generated was considerable, however, no synthesis of data was performed for this review. 
It is by design that the framework of scoping studies does not address this issue. 49,51  
Scoping studies are meant to provide a narrative and descriptive account of available 
literature on a topic over a greater range of study designs in comparison to systematic 
reviews, which focus on a narrowly defined question. 49   
2.6. Conclusion 
The literature on this topic has grown rapidly in the past five years. This scoping 
review has identified the prevalence of non-adherence in cognitively impaired older 
adults, adherence assessment techniques, and barriers and interventions available to 
tackle non-adherence amongst older adults with cognitive impairment. Although there is 
a growing body of literature, many questions remain unanswered. First of all, there is a 
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lack of gold standard in assessing adherence. This shortcoming is a challenge because 
comparison among studies using different assessment tools limits the ability to make 
cross study comparisons and to draw generalizable conclusions. Secondly, a number of 
barriers specific to cognitively impaired older adults were identified through this review. 
Impaired cognition was identified as a key predictor of non-adherence. This predictor is 
especially important because impaired cognition hampers the ability to manage 
medications thereby leading to an increased risk of non-adherence. Other barriers such as 
the presence of a cognitively impaired caregiver, which in most cases is the spouse of the 
patient, is also a risk factor that facilitates medication non-adherence. Although the 
spouse of the caregiver is at equal risk of non-adherence, not much work has been done 
on this topic.  Lastly, many interventions tackling medication non-adherence have been 
studied, however there is a lack of randomized control trials to support the effectiveness 
of these in cognitively impaired older adults. It is crucial to focus future research on these 
identified gaps to better describe medication non-adherence problems in this population.  
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581 titles identified through electronic 
databases 
535 titles after duplicates removed 
112 abstracts reviewed 
423 titles excluded 
60 full-text articles assessed for eligibility  
52 abstracts excluded 
42 articles, and 2 conference 
proceeding included in the final 
review 
 
16 full texts articles excluded 
- 8 articles only described 
discontinuation and 
persistence of 
cholinesterase inhibitors 
- 1 article only described 
about complexity of drug 
regimen and cognitive 
impairment 
- 7 articles were in different 
languages (4 Spanish 
articles, 2 Japanese articles 
& 1 German article) 
Figure 2: Study flow used in the scoping review 
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Table 1: Adherence assessment tools used in the literature 
Studies 
Self-
report/care-
giver report 
Electronic 
monitoring 
Pharmacy 
refill 
history 
Pill 
count 
Blood/urine 
medication 
monitoring 
Clinical 
outcome 
Health provider’s 
report 
Park et al 47    Yes           
Boucher et al 48       Yes Yes       
Barat et al 23   Yes           Yes 
Salas et al 71      Yes         
Raehl et al 72  Yes             
Cooper et al 46  Yes             
Insel et al 65    Yes           
Cotrell et al 64  Yes     Yes       
Ganguli et al 63  Yes           Yes 
Hutchison et al 62  Yes             
Hayes et al 52    Yes           
Poon et al 61      Yes         
Borah et al 60      Yes         
Kim et al 59      Yes         
Schwalbe et al 13    Yes       Yes   
Jerant et al 58        Yes       
Shah et al 75      Yes         
Foebel et al 76            Yes   
Le Couteur et al 57      Yes         
Mehuys et al 21  Yes     Yes     Yes 
Thiruchselvam et al 66  Yes           Yes 
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Kakkad et al 82      Yes         
Hain et al 40  Yes             
Boada et al 55  Yes             
Haider et al 54      Yes         
Kim. 53  Yes Yes   Yes     Yes 
Sattler et al. 69      Yes         
Campbell et al 18   Yes   Yes         
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Figure 3: Literature review map 
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Table 2: Barriers to adherence 
Authors Year Title Country Key findings 
Boucher L, Renvall 
MJ, Jackson JE. 48   
1996 Cognitively impaired spouses as 
primary caregivers for demented 
elderly people. 
 
USA Dementia patients with cognitively impaired spouses experienced 
difficulty with medication compliance (p=0.041) compared to 
cognitively intact spouses  
Barat I, Andreasen F, 
Damsgaard EM. 23   
2001 What doctors believe and 
patients actually do 
Denmark 
 
Positive association was found between non-adherence and the use 
of three or more drugs [OR 2.5; 95% CI (1.5,4.1)], prescriptions 
from more than one physician [OR 2.5; 95% CI (1.3,4.8)], and 
probability of dementia [OR 9.0; 95% CI (1.1,72.5)] 
 
Salas M, In’t Veld BA, 
van der Linden PD, 
Hofman A, Breteler M, 
Stricker BH. 71  
 
2001 Impaired cognitive function and 
compliance with 
antihypertensive drugs in 
elderly: The Rotterdam study.  
Netherlands Increased risk of non-compliance in cognitively impaired older 
adults [Adjusted RR 2.0; 95% CI (1.4, 2.8)]  
 
Increased risk in those who lived alone [OR 2.9; 95% CI (1.2, 7.5)] 
Cooper C, Carpenter I, 
Katona C, et al. 46  
2005 The AdHOC study of older 
adults’ adherence to medication 
in 11 countries. 
UK  Problem drinking (OR= 3.6), not having a physician review their 
medication (OR = 3.3), Cognitive impairment (OR=1.4) for every 
one-point increase in impairment), good physical health (OR = 1.2), 
being unmarried (OR 2.3) 
 
Ganguli M, Du Y, 
Rodriguez EG et al. 63  
2006 Discrepancies in information 
provided to primary care 
physicians by patients with and 
without dementia: The Steel 
Valley Seniors survey. 
 
USA A discrepancy in adherence assessment was found between home 
visit and chart review in 40.9% of patients with chart dementia 
diagnosis. 
Grocki JH, Huffman 
KK. 70  
2007 Medication adherence among 
older adults. 
USA Medication non-adherence was attributed to: Intentional caregiver 
neglect (37%)> dementia (24%) > mental illness and family and 
social support (15%)> theft (6%) > drug abuse (3%) 
 
For the oldest men age, 81, dementia was the predominant barrier. 
 
Hayes TL, Larimer N, 
Adami A, Kaye JA. 52  
 
2009 Medication adherence in healthy 
elders: Small cognitive changes 
make a big difference. 
 
USA Low Cognitive Functioning group were at higher risk of non-
adherence as compared to High Cognitive Functioning group  
[RR = 4.1 CI 95%(3.47, 4.78)]. 
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Poon I, Lal LS, Ford 
ME, Braun UK. 61  
2009 Racial/ethnic disparities in 
medication use among veterans 
with hypertension and dementia: 
A national cohort study. 
USA Medication adherence was significantly lower in African 
Americans than whites in all classes except for Anginotensin 
Receptor Blockers, loop diuretics, and PSDs (p < 0.05).  
 
Being Hispanic was associated with significantly lower adherence 
rates than whites for Dihydropyridine CCBs [OR=0.69 CI(0.53, 
0.89)] and acetyl cholinesterase inhibitors [OR= 0.77 CI(0.61, 
0.96)] 
 
Borah B, Sacco P, 
Zarotsky V. 60  
2010 Predictors of adherence among 
Alzheimer’s disease patients 
receiving oral therapy. 
USA 
 
Compared to patients <75 years, patients >86 years were likely to 
be more adherent (OR= 1.401, p<0.001).  
 
Other factors found to be positively associated with the probability 
of adherence to AD medications were male gender (OR =1.175, 
p<0.05), overall pill burden (OR= 1.192, p<0.001), and a lower 
formulary tier status of the AD medication (OR=1.332, p<0.001) 
 
Kim HK, Park JH, 
Park JH, Kim JH. 59  
2010 Difference in adherence to 
antihypertensive medication 
regimens according to 
psychiatric diagnosis: Results of 
a Korean population-based 
study. 
 
 
 
South Korea Lower MPR was associated with patients with Alzheimer Disease 
[Adjusted OR= 0.865; 95% CI (0.791, 0.945)] and vascular 
dementia [Adjusted OR= 0.785; 95% CI(0.672, 0.917)] 
Schwalbe O, 
Scheerans C, Freiberg 
I, Schmidt-
Pokrzywniak A, Stang 
A, Kloft C. 13  
 
2010 Compliance assessment of 
ambulatory Alzheimer patients 
to aid therapeutic decisions by 
healthcare professionals. 
 
Germany For 10 mg and 5 mg donepezil once-daily dosing, the estimated 
forgiveness of donepezil was 80% and 90% daily compliance or 
two and one-dosage omissions at steady state, respectively. 
Hawkins LA, Kilian S, 
Kashner TM, et al. 85  
2011 Is cognitive impairment 
associated with medication 
adherence in outpatients with 
heart failure? 
USA In patients where pill count could be completed, medication 
adherence was associated with cognitive impairment (r=50.24, p-
value 0.004). 
 
In outpatient veterans with Heart Failure, previously undiagnosed 
CI is prevalent and associated with medication adherence 
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Jerant A, Chapman B, 
Duberstein P, Robbins 
J, Franks P. 58  
2011 Personality and medication non-
adherence among older adults 
enrolled in a six-year trial. 
USA Each five year increment in participant age was associated with a 
6.7% greater probability of non-adherence (95% CI [2.4, 11.0]). 
 
Lower cognitive function was also associated with non-adherence: 
a 1 SD decrease in mental status exam score was associated with a 
3.0% increase in the probability of non-adherence (95% CI [0.2, 
5.9]). 
 
Shah SN, Knoth RL, 
Margolis J, Alvir J, 
Lenhart G. 75  
2011 The effect of Alzheimer’s 
disease medication cost-share 
burden on chronic disease 
medication adherence and 
clinical outcomes. 
USA High AD Out Of Pocket costs (>$26) had significantly worse 
adherence and persistence on their diuretics and adrenergic blockers 
(p<0.05) than those with low OOP costs (<$6). 
 
Increased hospital admissions, inpatient days and ER visits were 
associated with low AD medication adherence rates (p<0.001). 
 
Alosco ML, Spitznagel 
MB, van Dulmen M, et 
al. 25  
2012 Cognitive function and 
treatment adherence in older 
adults with heart failure. 
USA Reduced performance on attention (β  = .26, p  = .01), executive 
function (β  = .18, p  = .04), and language (β  = .22, p  = .01) were 
associated with poorer overall adherence. 
 
Foebel AD, Hirdes JP, 
Heckman GA. 76  
2012 Caregiver status affects 
medication adherence among 
older home care clients with 
heart failure 
 
Canada  Among individuals with MCI, having a caregiver at the same 
residence reduced medication non-adherence. Additionally, 
caregiver stress was significantly associated with higher rates of 
non-adherence. 
 
Le Couteur DG, 
Robinson M, Leverton 
A et al. 57  
2012 Adherence, persistence and 
continuation with cholinesterase 
inhibitors in Alzheimer’s 
disease. 
 
Australia Adherence to cholinesterase inhibitors was reasonable after the 
commencement of the treatment. 
Mehuys E, Dupond L, 
Petrovic M, et al.21  
2012 Medication management among 
home-dwelling older patients 
with chronic diseases: Possible 
roles for community 
pharmacists 
Belgium The overall mean adherence per patient was very high (98.1%). 
Seventy-six percent (76%) of patients had an acceptable knowledge 
of the indication for at least seventy-five percent (75%) of their 
medication. 
 
The participants reported several practical problems with drug 
taking: difficulties with vision (32.0%), blister opening (12.1%), 
tablet swallowing (14.8%), tablet splitting (29.7%)[represents % of 
patients who have to split tablets]) and distinction between different 
drug packages (23.4%). 
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Thiruchselvam T, 
Naglie G, Moineddin 
R et al. 66  
2012 Risk factors for medication 
nonadherence in older adults 
with cognitive impairment who 
live alone. 
 
 
 
 
Canada Risk of medication non-adherence in patients taking four or more 
medication [OR 2.58; 95% CI(1.3-5.29)] 
 
Risk of medication non-adherence in patients with previous 
occurrence of non-adherence in past year [OR=2.58; 95% CI (1.18-
5.62)] 
 
Haider B, Schmidt R, 
Schweiger C, Forstner 
T, Labek A, Lampl C. 
54  
2013 Medication adherence in 
patients with dementia: An 
Austrian Cohort study. 
Austria Compliance rate for ChEIs: 28.3%-35.3% 
 
At 12 months, highest discontinuation rate was seen in patients 
taking rivastigmine (67.3%), and memantine had lowest 
discontinuation rate (45%) 
 
Kim SH. 53  2013 Variables influencing treatment 
adherence in patients with 
alzheimer’s disease. 
South Korea Poor inter-rater agreement: Kappa coefficients were 0.382 (pill 
count vs. MEMS), 0.382 (clinician rating scale vs. MEMS) and 
0.256 (self-report vs. MEMS). 
 
Gender difference was correlated with adherence. 
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Table 3: Interventions described in literature 
Authors Year Title Country Key findings 
Insel KC, Cole L. 65  2005 Individualizing memory 
strategies to improve 
medication adherence. 
 
USA Adherence increased from a mean of 64.5% to that of 
78% (Z-score = 2.42) 
 
 
Blesa R, Ballard C, 
Orgogozo JM, Lane R, 
Thomas SK. 78  
2007 Caregiver preference for 
rivastigmine patches 
versus capusles for the 
treatment of Alzheimer 
disease. 
Spain 72% of caregivers preferred the patch to capsules overall. 
 
The patch was preferred to capsules because: 
ease of use (p<0.0001) and ease of following the schedule 
(p < 0.0001).  
 
Caregivers indicated greater satisfaction overall (p 
<0.0001) and less interference with daily life (p < 0.01) 
with the patch vs. capsules. 
 
Articus K, Baier M, 
Tracik F, Kuhn F, 
Preuss UW, Jurz A. 77  
2011 A 24-week, multicenter, 
open evaluation of the 
clinical effectiveness of 
the rivastigmine patch in 
patients with probable 
Alzheimer’s disease 
Germany At week 24, patients treated with the Rivastigmine patch 
showed improvements on MMSE [During screening 
(19.6 points) and at week 24 (20.9 point)], Alzheimer’s 
Disease Cooperative Study–Activities of Daily Living 
(ADCS-ADL) [baseline (50.3 points) and at week 24 
(51.4 points)], Alzheimer’s Disease Cooperative Study–
Clinical Global Impression of Change (ADCS-CGIC) and 
(Trail Making Test Part A) TMT-A scores.  
 
Tolerability: Mean Alzheimer's Disease Caregiver 
Preference Questionnaire (ADCPQ) scores improved 
from baseline (12.2 points) at week and at week 24 (30.7 
points).  
 
Caregivers reported acceptance, preference and 
satisfaction with the patch. 
 
Kamimura T, Ishiwata 
R, Inoue T. 84  
2012 Medication reminder 
device for the elderly 
patients with mild 
cognitive impairment  
Japan Changes in Self Administration Medication Rate 
(SAMR) 1 month after onset of device use: 
10 users (55.5%) showed 100% improvement in SAMR 
values. The SAMR values for 5 users (27.8%) showed an 
improvement of <100%  (Range: 28.6%- 85.7%). 
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Changes in SAMR at 3 months: Nine users (49.9%) 
maintained SAMR values of 100%, and 1 user (5.6%) 
showed 100% improvement in SAMR values. 
 
Kakad PP, Harpe SE, 
Slattum PW. 82   
2012 Impact of calendar blister 
packaging (CBP) on 
adherence with 
antihypertensive 
medications in older 
adults treated for 
dementia. 
 
USA Calendar Blister Packaging use was associated with 10% 
higher MPR rate as compared to vial use. 
 
Adams R, May H, 
Swift L, Bhattacharya 
D. 83  
2013 Do older patients find 
multi-compartment 
medication devices easy 
to use and which are the 
easiest? 
UK Cognitively impaired participants reported more 
difficulty in opening the Venalink [ 9(3.5, 10) in CI vs. 7 
(2, 8.25) in non impaired] and removing medication from 
the Nomad [6.5 (3, 9.75) vs. 4.5 (1.75, 8) in non 
impaired.] 
 
Prior of MMDs use made it easier to use: Venalink 
[−2.03, (−3.94–0.13)], Nomad [-1.56,  (-3.11, -0.1)] 
 
Best overall rating: Dosett (54%) > Venalink (14%) > 
Nomad (10%) 
 
Boada M, Arranz FJ. 55  2013 Transdermal is better 
than oral: Observational 
research of the 
satisfaction of caregivers 
of patients with 
Alzheimer’s disease 
treated with rivastigmine. 
 
Spain Greater satisfaction with transdermal vs. oral 
rivastigmine (72.5± 14.1 vs. 65.2± 12.5, p =0.001) 
 
Higher adherence with transdermal patch vs. oral (65.0 
vs. 41.4%, p=0.001) 
Czeche S, Schuessel 
K, Franzmann A, 
Burkart M, Schulz M. 
80  
2013 Dosage strength is 
associated with 
medication persistence 
for ginkgo biloba drug 
products. 
Germany Risk for non-persistence was reduced in patients 
receiving 240 mg products compared to 120 mg (HR = 
0.63; 95% CI 0.57 – 0.70) 
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CHAPTER 3: FEASIBILITY OF DETERMINING 
MEDICATION ADHERENCE USING PILL COUNT 
VERSUS PHARMACY REFILL DATA IN A PRIMARY 
CARE-BASED MEMORY CLINIC 
 
3.1. Introduction 
3.1.1. A brief background on the Center for Family Medicine’s Family Health 
Team’s (CFFM FHT) Memory Clinic 
The CFFM FHT’s memory clinic is a novel primary health care model, which was 
developed in Kitchener, Ontario to assist the patient’s family physician in coping with the 
complex challenges associated with dementia care and to reduce reliance on specialist 
referrals to tertiary care centers, which are often inaccessible due to long wait times (6 to 
12 months). 68  The memory clinic team at the Kitchener CFFM FHT is comprised of a 
physician, nurses, social worker, occupational therapist and pharmacists. Professionals 
from each discipline work in collaboration to manage the existing comorbidities in 
patients with dementia, to reduce polypharmacy, and to address the related risks of non-
adherence and behavioral and psychological symptoms of dementia. 68  In particular, the 
role of the pharmacists is to design and implement appropriate pharmacotherapeutic 
regimen to manage existing chronic conditions along with a strong emphasis on assessing 
medication-taking behaviour and promoting medication adherence. 68  A summary of the 
model is shown in Figure 3. 
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Memory Clinic Operational Model 
 The clinic operates three to four days a month on average, with six patients 
scheduled on each clinic day. The patients seen at the clinic are referred by their family 
physician who has identified memory or cognitive changes, or if there is a family concern 
regarding changes in memory and cognitive ability or a difficulty in managing a patient 
with dementia. The referrals are sent electronically using an electronic medical record 
(EMR) to the memory clinic-scheduling nurse, who in turn, reminds the patient and their 
caregiver a day or two before their appointment through a phone call. The patient and 
caregivers are also reminded to bring all prescription medications, vitamins, and over-
the-counter medications in their current containers during their visit to the clinic. 68  
 On a typical clinic day, the memory clinic team meets the patient and their 
caregiver at the beginning of the appointment during which time the clinic team is 
introduced and a history of presenting complaints is gathered. The initial assessments last 
for 5 to 10 minutes, after which the patient and the caregiver dyad are split into two 
rooms where the social worker or the occupational therapist and the pharmacist interview 
the caregiver in one room and the nurse conducts cognitive testing on the patient in the 
other. During the pharmacist’s interview with the caregiver, the pharmacist obtains 
information regarding the patient’s overall function and emotional state and a 
comprehensive medication history, and assesses medication adherence by pill count, 
visual examination of blister packs and/or calling the patient’s pharmacy to gather past 
refill history. As the patient is being assessed for cognitive impairment and the degree of 
impairment is unknown prior to the appointment, he/she may not be able to recall or 
present insights regarding medication-related concerns, therefore, the interview is carried 
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out separately with the caregiver. The patient is, however, involved in the decision 
making process. Once all the relevant data are obtained, the team discusses the case with 
the physician and input from all the team members is used to obtain a holistic picture of 
the patient’s clinical, functional and social status. The physician then establishes a 
working diagnosis (e.g., MCI, Alzheimer’s disease, mixed dementia, etc.), and a 
complete treatment plan is developed and optimized with inputs from the pharmacist. In 
the end, the results are disclosed to the patient and the caregiver, and follow-up visits are 
scheduled at the memory clinic based on the diagnosis, and type and severity of the 
problems. 68 
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Figure 4: Memory clinic operational model 
 
Used with permission (Appendix 2)  68  Rojas-Fernandez C, Patel T, Lee L. An innovative collaborative practice for clinical 
pharmacists in an interdisciplinary, primary care based memory clinic in Ontario, Canada. Ann. Pharmacother. 2012; 32(10):e262. 
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3.1.2. Pharmacist’s role in a Memory clinic 
 
The role of pharmacists has expanded in the recent decades and an increasing 
number of pharmacists are practicing with well-documented roles in interdisciplinary or 
multidisciplinary teams, such as heart failure programs, and hypertension clinics. 86,87  In 
addition, it has been demonstrated that having a pharmacist on a primary care team can 
lead to improvement in health outcomes. For instance, a study showed that having a 
pharmacist on a primary care based hypertension clinic improved blood pressure control 
in type 2 diabetes patients [OR = 2.6, 95% CI (1.3, 5)]. 86  Recently, Rojas-Fernandez et 
al described the role of pharmacists practicing in a novel interdisciplinary family health 
team-based memory clinic. 68  
From a pharmacotherapeutic perspective, a pharmacist practicing in a memory 
clinic is in a unique position to assess the numerous challenges presented in patients with 
dementia and/or memory concerns for several reasons. 68  The most crucial challenge is 
that dementia commonly exists with other co-morbidities. Managing these complex 
comorbid conditions require an increased number of pills, which may affect medication 
management in presence of reduced memory, and this mismanagement of drugs may lead 
to negative health outcomes. Adverse events as a result of poor management of 
medications have shown to increase the rate of hospitalization.10 Other challenges such as 
the natural progression of cognitive impairment, falls, delirium and polypharmacy also 
exist in this population. Appropriate medication prescribing is necessary in order to deal 
with these challenges along with a need to assess the patient’s medication-taking 
behaviour. This requires the pharmacological expertise of a skilled pharmacist because 
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the clinical guidelines are devised for a single disease state and not for a complex set of 
diseases.  
Furthermore, a pharmacist is also in a unique position to assist in recognizing 
problems related to medication management and adherence. 88,89  At the memory clinic, 
the pharmacist follows a comprehensive, patient-focused method to assess the medication 
regimens in order to deal with the unique challenges of this complex patient population. 
To ensure that patient assessment is thorough, it is important to gain an insight about the 
patient’s medication-taking behaviour. Generally, the pharmacist collects data in two 
broad steps, namely pre-clinic data gathering and data gathering during the clinic visit 
(Figure 4). In particular, adherence assessment occurs on the appointment day of the 
patient. 
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Figure 5: Pharmacist's assessment of patient's medication regimen 
 
Used with permission (Appendix 2)  68 Rojas-Fernandez C, Patel T, Lee L. An innovative collaborative practice for clinical 
pharmacists in an interdisciplinary, primary care based memory clinic in Ontario, Canada. Ann. Pharmacother. 2012.;32(10):e262.  
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3.1.3. Medication adherence in cognitively impaired older adults 
 
Research on medication non-adherence among older adults has attracted a significant 
amount of interest in the recent years. 90  Increased prevalence of chronic conditions 
coupled with greater pill burden has been cited as a reason for this. 5  Furthermore, a 
factor unique to this population is the higher prevalence of cognitive impairment, which 
has shown to affect medication-taking behaviour of these patients. 17,18  Although 
cognitive impairment is a key barrier to medication adherence in older adults, many 
details of patient behaviour pertaining to taking medications remain untouched, 
especially in clinical settings. With novel practice sites such as memory clinics now 
recognizing adherence as a key determinant of health outcomes, it is clear that there is a 
lack of studies describing various aspects of medication adherence observed in patients 
seen with cognitive impairment. A major limitation to observing these factors is a lack of 
gold standard. Furthermore, it becomes increasing difficult to determine which adherence 
assessment technique is most suitable in this setting. The literature suggests triangulation 
of two or more adherence methods to obtain an accurate estimate of patient 
behaviour.27,41  For this reason, the pharmacists practicing in memory clinics use pill 
count and pharmacy refill data to ascertain patient adherence. However, the role of the 
pharmacist in the clinic also involves a number of other tasks to ensure a complete and 
thorough assessment of patients. For this reason, it is crucial to determine which method 
is most feasible in this clinic. Other aspects such as the interventions used by the 
caregiver of the patients seen at the memory clinic also remain unanswered.  
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3.1.4. Pharmacist’s assessment of adherence in the memory clinic setting 
 
A number of adherence assessment instruments have been described in the current 
literature and they have been broadly classified as direct and indirect methods. Direct 
methods confirm that the patient has consumed the medication, whereas indirect methods 
are proxy measures and do not demonstrate the consumption of the medication. 27  
Although several strategies of measurement have been described and studied across 
various populations, clinicians are faced with a dilemma of choosing the most feasible 
method in a community setting, as there is no “gold standard” for measuring medication 
adherence. 27   
Overall, adherence assessment provides insights that outcome-monitoring alone 
cannot; yet it remains to be an estimate of a patient’s true medication-taking behaviour. 
No single measurement technique is optimal. Although direct measures overcome this 
limitation by providing true values of actual drug consumption, several factors restrict its 
use in clinical practice. 41  For example, direct methods such as biological assays are 
invasive (e.g. blood monitoring), impractical (e.g. analyzing urine samples) and 
expensive in routine primary care-based practice. Conversely, although indirect 
adherence measures address some of these limitations of direct methods by providing an 
economical and practical medium of adherence assessment, they provide only an estimate 
rather than the true value of patient’s behaviour. A multi-method approach combining 
different measuring techniques has been suggested as a means of identifying non-
adherent patients. Currently, the pharmacists at CFFM’s FHT’s memory clinic uses two 
common methods of assessing adherence: pharmacy refill data and pill count data. Prior 
to the visit, all the patients are reminded to bring their pill bottles and/or blister packs to 
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their appointment. The pharmacy is also contacted to ascertain the refill dates for 
medication adherence assessment. Although triangulation between adherence methods 
can improve the accuracy of the measurements, it may not be possible to carry out both 
techniques in a busy clinic setting. Furthermore, if only one of the aforementioned 
adherence methods has to be used, there is a need to know whether the scores assessed by 
both approaches correlate or not. No studies on this topic have been conducted to date.  
In addition, the literature points out that cognitively impaired older adults who are 
aware of their memory impairment have higher adherence rates than those who deny 
memory impairment. 48,91  These patients and/or their caregivers are known to use various 
interventions in order to maintain optimum adherence, for example, use of calendar 
blister packs and weekly pill boxes.16,48 However, there is also a lack of proper studies 
that describe the interventions used by the caregivers, particularly in a memory clinic 
setting. 
Given the uncertainty regarding the best management of adherence in older adults 
with cognitive impairment, the primary goal of this project was to determine the most 
feasible adherence assessment method that could be utilised in a primary care based 
memory clinic. The specific objectives were to: 
a. Compare the feasibility of using two different methods for assessing medication 
adherence in older patients with cognitive impairment. 
b. Describe different adherence-enhancing methods used by caregivers, spouses of 
patients, or by patients. 
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3.2. Methods 
 
3.2.1. Study design 
 
Before the commencement of the study, ethics clearance was obtained through the 
Office of Research Ethics at the University of Waterloo (ORE #19939, Appendix 3) and 
the Physicians’ Board of the CFFM FHT.  
The study design adopted for this study was a cross-sectional study design. A 
cross-sectional study design involves sampling patients irrespective of their disease status 
and is studied at a particular point in time. 92  This provides a snapshot of both the 
exposure and outcome at the same time for a given sample of participants. 92  Cross-
sectional studies are mainly used if the purpose of the study is to describe a novel setting 
or is to determine the prevalence of the outcome of interest for a population at a given 
point in time. 93  As the purpose of the study was to describe the feasibility of assessing 
adherence in a novel clinic setting, a cross-sectional study was deemed appropriate. 
3.2.2. Sample size estimation 
 
 Considering the lack of studies on the current topic in the present literature, a 
±10% difference in the estimated adherence scores was assumed to facilitate a sample 
size calculation. The following formula was used to determine the sample size: 
n = 2[(za + zb) σ/ Δ]2  
where, σ = standard deviation; Δ = difference between means of pill count and MPR 
The estimated sample size was 39, when the σ/Δ = 2.5, α=0.05 and ß=0.2 
 
3.2.3. Participants 
 
 Patients visiting the memory clinic in Kitchener, ON were recruited to take part in 
this study. Prior to data collection, prospective participants and their caregivers were 
 54 
invited by the pharmacist or nurse to read an information letter (Appendix 5 and 6) 
explaining the study rationale and objectives, and were required to indicate their consent 
to participate by signing a consent form. In a situation where the participant had severe 
cognitive impairment (if shown in the EMR chart and confirmed by the pharmacist), the 
caregivers were asked to read the information letter and sign on behalf of the patient in 
the presence of a witness (usually, the pharmacist or the nurse) (Appendix 7). 
Inclusion criteria were laid out in accordance with the objectives of the study. The 
main objective of the study was to compare two adherence assessment instruments (MPR 
and pill count) and to determine which is the most feasible in this clinic setting. The 
study aimed at determining adherence patterns in patients who lived independently, as 
patients living in long term care usually have their medications managed by the long term 
care (LTC) nursing staff. Adherence assessment of over-the-counter (OTC) medications 
was not possible as the adherence assessment methods involved the use of pill count data 
and pharmacy refill data. The data obtained through these methods do not allow for OTC 
adherence assessments, as the starting dates of OTC medications are usually unknown. 
Also, as the clinic specializes in dealing with patients with memory concerns, there was a 
higher chance that patients with severe impairment could also be scheduled. From an 
ethical point, it was of importance to obtain consent from the caregiver in addition to the 
patient. Therefore, the inclusion criteria used for recruiting the participants were: 
a) patients had to live independently, 
b) be 65 years or older, 
c) patients had to have at least one prescription medication and 
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d) patients who were able to give consent. In case the patient was severely impaired, 
their caregiver was asked to consent on the patient’s behalf. 
Patients were automatically excluded if they: 
a) were residing in long term care units, 
b) were less than 65 years old, 
c) did not report taking any prescription medications or had only reported to take 
OTC medications and 
d) did not consent to participate. 
3.2.4. Data collection 
 
A case report form was designed and developed (CRF) to collect data for the 
purpose of this study (Appendix 4). Prior to the appointment day, the study participants 
were contacted through a telephone call as a reminder to bring all their medication pill 
box/containers (both, prescription and OTC medications). 
 
Pill count data: All the prescribed medications were counted to gather pill count data. 
This data was applied to a formula (Section 3.2.6).  
 
Pharmacy refill history: Information regarding refill history for all prescription drugs 
was obtained from the patient’s pharmacy. The pharmacies from where participants 
obtain their medications were contacted through telephone on the same day of their visit 
to the clinic. The following details were gathered from the pharmacy: 
a. last refill date, 
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b. refill date prior to the last filling date and 
c. the total days supply of medication during the refill period 
All the aforementioned data were entered in a CRF. Information related to participants 
was kept anonymous and confidential using a subject code (Month Year Number).  
3.2.5. Procedure 
 
The data collected for this project, involved information gathered by the 
pharmacist as part of routine clinical practice. The variables recorded for this study 
include patient’s demographics (age, sex, marital status, living situation, etc.), Montréal 
Cognitive Assessment (MoCA) score, Cornell score for depression, diagnosis, 
medications, and adherence data. The diagnosis and medications taken by the patients 
were ascertained using the electronic medical record (EMR) of the respective patients.  
On the day of regular clinic, the scheduled patients were first reviewed through 
the EMR to determine the eligibility criteria for inclusion. No data was collected at this 
point. Only in cases where the subject met all the listed inclusion criteria did the 
pharmacist or the nurse approach the subject and the caregiver to ask for consent. Patients 
with severe cognitive impairment were also included in the study, however, the caregiver 
had to consent on behalf of the patient. All patients and caregivers were provided an 
information letter explaining the purpose of the study and were asked to read through the 
letter before signing. In addition, the pharmacist on duty also explained the aim before 
asking the patient to sign the consent. It should be noted that all the patients visiting the 
clinic could not be approached as a result of patient irritability, and/or time restrictions on 
regular clinic days. 
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Once the consent was obtained, the necessary data was collected from the EMR 
and adherence data was computed using pharmacy refill history and pill count. The 
pharmacies of the respective patient were contacted in order to obtain pharmacy refill 
history. In case a patient did not bring the pill bottles, consent was still obtained in order 
to ascertain their refill history. MoCA and Cornell testing carried out on the day of 
appointment by the nurse were collected at the end. 
3.2.6. Outcome variables 
 
The primary outcome measure was feasibility, which was defined as the ability to 
collect the data necessary to compute medication adherence of the patients seen at the 
memory clinic.  
Assessment of adherence using pill count data was considered to be feasible if the 
participant presented with the pill bottles in order to gather the data required to compute 
adherence, for example, the number of remaining pills in the pill bottle, the date the drug 
was filled and the initial quantity of the pills dispensed.  
Assessment of adherence using pharmacy refill history was considered to be 
feasible if all the data (e.g. the last refill date, the refill date prior to the last and the 
quantity dispensed) necessary to compute adherence could be collected on the phone by 
calling the participant’s pharmacy.  
The secondary outcome was patient adherence. Medication adherence using pill 
count data was estimated using the formula below:  
Number of pills dispensed – number of pills present in the bottle / number of pills 
expected to be taken according to the prescription instructions 
 ≥ 80% is considered adherent as per accepted standards. 27,64,94   
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Medication adherence using pharmacy refill data was estimated using the MPR. 
MPR is calculated as: 27,43,46    
all days supply / the number of days between refills (i.e. days between last 
prescription dispensed and the appointment day).  
 ≥ 0.8 (80%) is considered adherent as per accepted standards.  27,43,46  
3.2.7. Analyses 
 
Analysis was carried using IBM’s Statistical Package for Social Sciences (SPSS) 
version 22.0.0.0 for the Macintosh operating system. Analyses consisted of descriptive 
statistics to describe the patients’ baseline characteristics and adherence estimates. 
Descriptive statistics were used to summarize the feasibility of assessment methods, and 
the adherence strategies used by patients and/or caregivers. One-way analysis of variance 
(ANOVA) was conducted to compare the patient demographics in relation to their MPR 
scores. Pearson’s correlation analysis was used to compare the continuous patient 
variables such as age, MoCA score, Cornell scores for depression, number of chronic 
conditions and number of prescription medications with average MPR rates.  
Fischer-exact test was used to determine if there was an association between the 
non-feasibility of pill counts assessment and the causes of non-feasibility. As the cross-
sectional study collected continuous adherence data, correlation analyses were carried out 
to examine the strength and nature of the relationship between the adherence scores 
measured by pill count and MPR. Using the dichotomous cutoff to determine the 
adherence status, the study analyzed the agreement between the assessment techniques 
using kappa statistics. The percent agreement between average medication adherence 
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estimates obtained by the pill count method and pharmacy refill data, and Cohen’s Kappa 
coefficients were calculated. In absence of a gold standard, the Kappa coefficient is used 
to facilitate in describing the extent of agreement between these two different methods of 
assessing adherence. 95   
Kappa coefficient is calculate using the following formula 96,97 :  
Kappa = (%Agreement observed) – (% Agreement expected) 
100% – (% Agreement expected) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 60 
3.3. Results 
3.3.1. Study participants 
 
In total, 62 patients were approached to be included in the study during the memory clinic 
visits from September 2014 to June 2015. Of these, 39 met the inclusion criteria for 
analysis (Figure 5). The remaining 23 were excluded for the following reasons: 
  11 patients below age of 65;  
 seven LTC patients; 
 two patients with no prescription medications;  
 two repeats and; 
 one patient did not consent 
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62 patients seen at memory clinic during 
enrollment period 
 
41 eligible patients for the study 
39 included for analysis 
21 ineligible patients 
 
 11 patients <65 y.o. 10 
 7 LTC patient 
 2 with no Rx meds 
 1 patient did not 
consent 
 
2 repeats 
Figure 6: Recruitment flow chart 
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Our sample consisted mostly of patients with an average age of 79 years and had 
a somewhat balanced gender ratio (Table 4). Subjects were taking an average of 5.74 
prescription medications (Range 1-14) and were diagnosed with an average of 3.89 
chronic conditions (range 1-8). As expected, there was a significant positive correlation 
between the number of chronic conditions and the number of prescription medications (r 
= 0.521, p<0.01). Additionally, a caregiver accompanied most participants.  
Tables 5 and 6 provide the list and frequency of co-morbidites presented in the 
patient sample. The mean MoCA score of the total sample was 19.22 (range 3-29). Less 
than half of the patients seen at the clinic had Mild Cognitive Impairment (16, 41%).  The 
most common types of dementia seen in patients were mixed (18, 46.2%) and vascular 
(3, 7.7%). The most common co-morbid conditions among the patients were hypertension 
(25, 64.1%), depression (13, 33.3%), hyperlipidemia (13, 33.3%), and type II diabetes 
mellitus (9, 23.1%). 
 
 
 
 
 
 
 
 
 
 
 63 
 
Table 4: Demographics of participants 
Demographics Results [n (%, where applicable)] 
Age, y  
Range 65–91 
Mean (SD) 79.08 (6.83) 
MoCA score  
Range 3–29 
Mean (SD) 19.22 
Chronic conditions  
Range 1–8 
Mean 3.89 
Prescription medications  
Range 1–14 
Mean 5.74 
Sex, no. (%)  
Male 22 (56.4%) 
Female 17 (43.6%) 
Race, no. (%)  
Caucasian 36 (92.3%) 
South Asian  2 (5.1%) 
Asian 1 (2.6%) 
Marital Status, no. (%)  
Married 28 (71.8%) 
Widowed 9 (23.1%) 
Never married 1 (2.6%) 
Divorced 1 (2.6%) 
Living situation, no. (%)  
With spouse 22 (56.4%) 
Alone 10 (25.6%) 
With family 6 (15.4%) 
Other 1 (2.6%) 
Caregiver present at visit, no. (%)  
Yes 33 (84.6%) 
No 6 (15.4%) 
Caregiver type  
Spouse 18 (46.2%) 
Offspring 8 (20.5%) 
None 6 (15.4%) 
Both 4 (10.3%) 
Other 3 (7.7%) 
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Table 5: Percentages of cognitively impaired patients 
Level of cognitive impairment n (%) 
No impairment 2 (5.1%) 
MCI 16 (41%) 
Mild 13 (33.3%) 
Moderate 14 (35.9%) 
Severe 10 (25.6%) 
Type of dementia n (%) 
Mixed 18 (46.2%) 
Vascular  3 (7.7%) 
Alzheimer’s disease 1 (2.6%) 
 
 
Table 6: Diagnoses of participant 
Co-morbid diagnoses n (%) 
Hypertension 25 (64.1%) 
Depression 13 (33.3%) 
Hyperlipidemia 13 (33.3%) 
Diabetes Mellitus (Type 2) 9 (23.1%) 
Osteoporosis 9 (23.1%) 
Hypothyroidism 9 (23.1%) 
Coronary artery disease 6 (15.4%) 
GERD  6 (15.4%) 
Atrial Fibrillation 4 (10.3%) 
Anxiety  4 (10.3%) 
Benign Prostrate Hyperplasia 4 (10.3%) 
Congestive Heart Failure 2 (5.1%) 
Asthma 2 (5.1%) 
Gout 2 (5.1%) 
Peripheral Vascular Disease 2 (5.1%) 
Bipolar disorder 2 (5.1%) 
Peptic Ulcer Disease 2 (5.1%) 
Degenerative Disc Disease 1 (2.6%) 
Parkinson’s Disease 1 (2.6%) 
Stroke 1 (2.6%) 
Osteoarthritis  1 (2.6%) 
Chronic Pain 1 (2.6%) 
COPD 1 (2.6%) 
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3.3.2. Comparing categorical patient variables and MPR 
There was no association between the MPR rates and patient gender, living 
situation, marital status, race or dementia type or level of impairment (Table 7).  
 
Table 7: Correlations between categorical variables and MPR 
Patient variables Degrees of freedom F–value p–value 
Gender 1 0.349 0.559 
Living situation 3 0.534 0.662 
Marital status 2 0.523 0.598 
Race 2 2.625 0.087 
Type of dementia 3 0.617 0.609 
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3.3.3. Comparing continuous patient variables and MPR 
 The MPR scores were not correlated with any patient variables, including age, 
MoCA score, Cornell scores, number of chronic conditions or number of prescription 
medications (Table 8).  
 
Table 8: Correlations between continuous patient variables and MPR 
Patient variables Pearson’s coefficients p–values 
Age -0.204 0.226 
MoCA scores 0.099 0.579 
Cornell scores -0.107 0.567 
Number of chronic conditions 0.053 0.757 
Number of prescription medications -0.076 0.656 
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3.3.4. Feasibility of MPR vs. pill count 
MPR using pharmacy refill history was more feasible than pill count. MPR was 
determined to be feasible in 38/39 (97.4%) patients while pill count was feasible in only 
17/39 (43.6%) patients.  
Over half of the time, the patient was provided with blister packs rendering pill 
count as infeasible because of the materials available for the review (see 
Discussion)[14/22 (63.63%), (p<0.001)]. The second most common reason for non-
feasibility was that the patients forgot to bring their pill bottles [8/22 (36.36%), (p= 
0.028)] during their visit to the clinic.  
The study examined the time taken to assess adherence using pill count and refill 
data. It took an average of 5:27min (SD 2:27min) to complete a pill count (from the 
beginning of counting the pills to the end calculation) versus 3:30min (SD 1:28min) to 
complete adherence assessment using MPR (time taken from the beginning of the call to 
the end calculation) [p=0.006, 95% CI 0:40, 3:13].  
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Table 9: Descriptive of feasible assessment methods 
Method of assessment Results 
Pill Count  
Feasible 17 (43.6%) 
Not feasible 22 (56.4%) 
Reason for non-feasibility  
Blister packs 14 (63.63%) 
Forgot to bring pill bottles 8 (36.36%) 
Medication Possession Ratio  
Feasible 38 (97.4%) 
Not feasible 1 (2.6%) 
Reason for non-feasibility  
Missing information  1 (2.6%) 
Time taken  
Pill count 5:27  (SD 2:27) 
MPR 3:30 (SD 1:28) 
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3.3.5. Comparison of assessment techniques 
There was no correlation between the adherence scores measured by pill count 
and pharmacy refill data (r=0.058, p=0.476). Furthermore, there was no statistically 
significant association between the two scores  (r=0.241 p=0.476).  
An average of 81.6% (n=31) of patients were found to be adherent to their 
medications using MPR. On the other hand, only 60% (n=9) were adherent using pill 
count. The kappa coefficient showed no agreement between pill count and MPR (kappa= 
0.045, p=0.825).  
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Figure 7: Scatter plot between MPR and pill count 
 
 
Table 10: Percentage agreement between pill count and MPR 
 
            Pill count (n= 14) 
% (N) 
  
 Adherent 
≥ 80% 
Non-adherent 
< 80% 
Percent 
agreement 
Kappa 
MPR (n=14)     
Adherent (≥ 80%) 50 (7) 35.7 (5)   
Non-adherent (<80%) 7.14 (1)  7.14 (1) 57.4 0.046 (p=0.825) 
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3.3.6. Interventions used by caregivers 
 The interventions used as adherence aids as reported by the caregivers of 
patients/participants include blister packs, weekly pillboxes and miscellaneous 
interventions. Miscellaneous techniques involved the use of small circular pill boxes 
(n=1/3) intended for a once a time per day use (e.g., filled for lunch and supper), and 
placing pill bottles on a dining table to aid in remembering to take medications with 
meals (n=2/3). The most common adherence aid among the memory clinic population 
was the blister packs (14/38, 36.8%), followed by the weekly pillboxes (8/38, 22.1%).  
Since the study also involved the use of a dichotomous cutoff of 80% to define 
adherence status, we explored if there was an association between adherence and 
intervention type (Table 11). All 8 patients using weekly pill boxes were found to be 
adherent according to overall MPR scores. Twelve out of fourteen (85.71%) patients 
were found to be adherent when they were on blister packs and two out of three (66.7%) 
when caregivers used miscellaneous interventions. Out of the thirteen caregivers who did 
not use any adherence interventions, only 4/13 (30.8%) were found to be non-adherent to 
their medications. Data was missing for one patient, as the information on this could not 
be obtained from the patients or the caregivers. 
There was no difference in MPR rates between those who used interventions and 
those who did not (mean difference in adherence = 1.987%, 95% CI 5.10, 9.07, p=0.573). 
For the eight patients who used weekly pillboxes, the MPR rate was 6% higher than for 
those who did not (Mean difference in adherence = 5.66%, 95% CI 1.15, 10.17, 
p=0.002). There was no significant difference in MPR rates for the miscellaneous 
interventions, including those who used memory cues and small pillboxes. 
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Table 11: Interventions used by patients and caregivers 
 
Intervention used N (%) Adherent Non-adherent Fisher-exact 
test 
No intervention 13 (34.2%) 9 (69.2%) 4 (30.8%) .164 
Blister pack 14 (36.8%) 12(85.7%) 2 (14.3%) .483 
Weekly pill boxes 8 (21.1%) 8 (100%) 0 .161 
Miscellaneous 
interventions 
3 (7.9%) 2 (66.7%) 1 (33.3%) .467 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 73 
3.4. Discussion 
3.4.1. Summary of results 
The study revealed that the MPR method was more feasible than the pill count 
method. Pill count was infeasible mainly due to patients bringing unused blister packs or 
label of the blister pack during their visit to the clinic. The study also investigated the 
time taken to conduct these assessments and it was found that MPR took significantly 
less time than pill count. Further, there was no association between the adherence scores 
obtained using pill counts and using pharmacy refill data. The study also found that 
blister packs were the most commonly used adherence aids among caregivers, followed 
by weekly pillboxes and miscellaneous interventions. Correlation analysis did not find 
any difference in adherence rates amongst the different interventions used.   
3.4.2. Correlations between different variables and adherence 
Many interdisciplinary clinics that involve pharmacists on their team have a role 
to assess the medication regimen of the incoming patients. A memory clinic, in particular, 
sees older patients with memory concerns who are often burdened by a number of 
chronic conditions, which in turn results in a complex medication regimen. For these 
drugs to act optimally, adherence is required. Previous research indicates correlations 
between variables such as female gender, patients living alone, single marital status, and 
non-Caucasian race. For example, difference in female gender was associated with non-
adherence in one study involving Korean patients with Alzheimer’s disease. 53  Borah et 
al. have also shown that males are more likely to be adherent to their medication as 
compared to females (OR =1.175, p<0.05). 60 Other variables such as living situation, 
marital status, and race have also been shown to have an effect on adherence. A study 
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conducted in 11 countries demonstrated that living alone (p<0.001) and being unmarried 
(p<0.001) were negatively associated with adherence. 46  On further analysis, the results 
from logistic regression confirmed that being unmarried predicted non-adherence in older 
adults. 46  As pointed out by Poon et al., non-Caucasians were more likely to be non-
adherent to their medications, but the results from this study did not show any association 
of this sort. 61 This study, however, was unable to demonstrate any significant 
correlations between all the categorical patient variables and adherence rates. This could 
be as a result of the smaller sample size as compared to previous studies that involved 
larger study population.  
On examining correlations between MPR and continuous patient variables, no 
significant associations were observed. As shown by the study, there was no correlation 
between medication adherence and MoCA scores. These results conflicts with literature 
because the literature points out that those patients with lower cognitive function were 
shown to have lower adherence rates. 52  Moreover, many published studies and reviews 
have also confirmed that decreased cognition is a key factor leading to non-
adherence.17,18,47,48,98  This study has also been unable to demonstrate any association 
between age, number of chronic diseases and number of prescription medications. These 
results are in line with those of a previous study that was conducted in 11 countries, 
where no association were seen between the given variables and medication adherence. 46   
3.4.3. Feasibility of conducting pill counts versus MPR 
 In this study, the MPR method was found to be a more feasible method in 
comparison to pill count. The feasibility of MPR could be attributed to the readily 
available refill data from the pharmacies of the patients. The findings support the results 
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from previous studies, which have reported the ease of using refill data as an advantage 
of MPR in assessment of adherence. 90  Additionally, MPR was the only method available 
to assess adherence in patients who were either on blister packs or did not bring their 
medications during their appointment, further ascertaining the utility of easily available 
data to estimate patient adherence. Arguably, pill count could be conducted on patients 
who brought open blister packs, however, in the present study no participants had 
brought a used blister pack. Moreover, the findings from the study only found that MPR 
estimation took less time in comparison to pill count assessment on the clinic day. 
Currently, the evidence on the time taken to conduct MPR is not available in the literature 
and therefore, no comparison could be made. 
 On the other hand, pill count assessment could only be conducted for those 
patients who brought their medications. Previous studies have indicated that pill count 
could not be conducted for all their study participants, however, the reasons for 
unavailability were left unaccounted for. 34,99  This study determined the reasons for non-
availability. There is only one other study that has documented the reasons for non-
availability of pill count in the community setting and they include missing information 
(labels, containers) (9.5%), prescription just filled and not yet started (9.1%), old 
prescription combined with new (5.9%), unclear information (2.0%), subject objected to 
pill count (1.0%) and dates not available (0.8%). 90  The results from this memory clinic 
study are consistent with data obtained from the previous study, where the researchers 
found missing information (including missing pill bottles) as the main reason for non-
feasibility of pill count measure.90 
 76 
 Although the study found that MPR was more feasible in comparison to pill 
counts, it cannot be assumed that both the methods measure the same medication taking 
behaviour. As noted earlier, MPR measures the patient’s access to medications and not 
the actual consumption.  
3.4.4. Comparison of scores assessed using pill count and MPR 
As determining feasibility was the main objective of the study, it was also of 
importance to understand whether/if the scores obtained through these methods 
correlated. The results from the test did not show any correlation between the two tools.  
For diagnostic studies, it is common to conduct sensitivity, specificity, Positive 
Predictive Value and Negative Predictive Value tests in the presence of a gold standard. 97  
However, in this study these analyses could not be performed due to the lack of a gold 
standard adherence assessment tool. Instead, Kappa statistics was conducted on the tools, 
which revealed no agreement between the scores. The results from this study are in line 
with results of other studies, which have indicated a weak agreement between various 
indirect methods.  53  For instance, a study that involved a cohort of participants with 
probable and possible Alzheimer’s disease were assessed for adherence using medication 
event monitoring system (MEMS), pill count and self-report measurement. 53  The study 
showed weak agreement between MEMS and other measures of adherence. 53  Another 
study conducted in a community setting also showed no agreement between self-reports 
and pill count. 90  
A plausible explanation for no agreement between the adherence tools in this 
study could be that pill count and MPR measure different aspects of the patient’s 
medication taking behaviour. In other words, pill count assesses the patient’s ability to 
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follow the prescribed recommendations and/or dose, while MPR measures the ability of 
an individual to obtain medications on time or before they run out. Both of these methods 
do not assess the actual consumption, thus augmenting previous research by showing that 
adherence is a complex patient behaviour and this behaviour cannot be assessed using a 
single indirect measurement tool. Another reason that could explain the non-agreement 
between the tools is that there was a small observational sample in which both pill count 
and MPR were feasible (n=14). 
3.4.5. Interventions used by the patient and/or caregiver 
 Patients and caregivers were found to use several adherence aids, for example, 
blister packs, weekly pillboxes, and other interventions such as small pillboxes meant for 
single dose and placing medications on the dining table. Among these interventions, the 
most popular adherence aid was blister packs. The reason for this could be that the 
patients, who were previously identified as non-adherent by the memory clinic team, 
were recommended to use blister packs to achieve an optimum adherence rate. However, 
this study does not confirm the given claim. 
 Most patients in the study were found to be using an intervention to maintain their 
medication adherence. This particular finding can be correlated to other studies where it 
has been found that patients who were cognizant of their memory concerns were more 
likely to use adherence aids. For example, in a study involving 51 older adults, 
depression and memory anxiety predicted the increased likelihood of using adherence 
aids. 91  Furthermore, it was found that those who used adherence interventions were 
more adherent than those who did not but there was no statistically significant difference 
between adherent users and non-users. From the results, it was also shown that patients 
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using weekly pillboxes had significantly higher adherence rates as compared to any other 
intervention strategies. However, there was a huge difference between the number of 
weekly pillbox users in comparison to blister packs, or miscellaneous interventions. This 
can make the results unreliable and therefore this must be taken into account before 
generalizing from these results. Studies have also shown that weekly pillboxes may not 
be suitable for use in the cognitively impaired population. For example, the results from a 
study involving 27 older adults dwelling from the community showed that the 
participants with cognitive impaired would not benefit from organization boxes.64 The 
difficulty of use can also be supported by another study which showed that multi-
compartment pillboxes were difficult to use for participants with cognitive impairment.83 
Considering that memory clinic patients receive assistance from their caregivers to 
organize a weekly pillbox, these may still prove to be an effective strategy to improve 
adherence. 
Blister pack users were also shown to have a large proportion of adherent patients. 
This study showed that almost 86% of patients using blister packs were adherent to their 
medications. This shows that the recommendation made by the memory clinic team to 
use blister packaging is an effective strategy when non-adherence is recognized. Further, 
results from this study corresponds to a study by Kakkad et al which showed Calendar 
blister packs users with cognitive impairment had 10% greater adherence rates than those 
who did not use blister packs. 82  Caution should be taken in interpreting the results, as 
this was not a pre- / post-intervention study. A small proportion of participants used 
memory cues and other non-defined interventions to manage medications. The results 
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from this study on miscellaneous interventions are inconclusive, as the number of 
participants using these interventions was low.  
3.4.6. Clinical implications on medication adherence assessment 
Although the patient refill data was readily available in most cases, there were 
several limitations of using MPR in clinical settings that need to be addressed. For 
example, the study found that MPR calculation was not possible in case of one patient 
whose refill dates were missing as a result of a change in pharmacies. As MPR 
calculation requires two refill dates and the total days’ supply for one drug, any one 
missing variable can lead to failure in calculating adherence scores. This can be true in 
this population, where a patient may move from independent living to a long-term care 
and consequently changing the pharmacy. Although, this particular patient had not 
moved into a longterm care facility, it provides an insight for other patients who may 
move into one in the future.  
Another inherent limitation of MPR is that it does not necessarily measure a 
patient’s medication use. The data from the pharmacy cannot infer whether the patient is 
or is not consuming the medications according to the given recommendations. There is a 
chance that the patients may be hoarding the pills or dumping them. Not only that, 
patients may also fill their prescriptions some time before needed, which can lead to 
overestimation of adherence. Furthermore, a number of memory clinic patients were on 
blister packs. Many pharmacies have a system by which the blisters are filled on a regular 
interval days. The problem with this automation is that, the pick up dates or the delivery 
dates are not recorded by the pharmacies, questioning the reliability of MPR assessment 
in blister pack patients. To the pharmacist’s best estimate, it can be assumed that the 
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patient is taking the medications and not dumping them based on the clinical outcomes of 
the chronic disease. However, there can be patients who do not have a large number of 
chronic conditions or have conditions that cannot be monitored through a clinical 
outcome, making it difficult for the pharmacist to estimate the patient’s medication taking 
behaviour. For example, adherence patterns can be estimated for chronic conditions such 
as hypertension where the blood pressure could be used as an end point as a measure of 
adherence. However, conditions such as dementia have no clinical outcome measures that 
can complement adherence measures. 
Pill count is a simple method to administer in a clinical setting. The reason for this 
is that adherence calculation requires the refill date printed on the pill bottles, and the 
number of pills remaining in the pill bottle. Researchers have shown that pill count is one 
of the simplest methods to assess adherence, both in practice and research. 27,41  Despite 
this, the pill count method largely relies on the patient’s/caregiver’s ability to recall and 
bring the pill bottles to the clinic. As noted, the clinic examines patients with declining 
memory and it should not be a surprise that many patients fail to bring their pill bottles 
during their appointment. Also, pill count could not be conducted in patients who were 
using blister packs. A plausible reason for this was that the blister packs are usually 
dispensed as two weeks’ or four weeks’ supply and on most occasions, patients did not 
bring all the blister packs. They either brought an unused blister pack or a list of 
medications they were taking. This made pill count assessment impossible to conduct. 
Another limitation of the pill count method is that the patient population seen at the 
memory clinic is diagnosed with an average of four chronic conditions for which they 
consume an average of six medications. Results from the study showed that conducting 
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pill counts on such a large number of medications can take significantly more time, 
which limits its practicality in a busy clinical setting. Furthermore, pill counts share the 
same limitation as MPR in that one cannot truly assess whether the patient is consuming 
the medication or not.  
Although compromised by these disadvantages, pill counts may provide rich and 
useful information on patient’s medication-taking behaviour at certain times. For 
example, the number of pills present in the bottle defines whether the patient consumes 
the right dose of medications. Several medications also require pill splitting in order to 
deliver the right dose and this can be verified using pill count. Pill counts also give an 
estimate of the current medication-taking behaviour of the patient rather than in 
retrospect as in case of MPR.  
Previous studies have shown a lack of agreement between several indirect 
techniques. This was also the finding of the present study. As one would assume that 
there must be a strong agreement and a high correlation between pill count and MPR, 
however this study showed otherwise. It is clear from the literature that no one-
assessment tool is successful in differentiating non-adherent from adherent patients. 
Therefore, it is suggested to triangulate two or more adherence assessment methods to 
ascertain patient adherence. 
3.4.7. Strengths 
This was the first of its kind study where pill count and pharmacy refill history 
were compared in a memory clinical setting. Previous studies have compared several 
indirect techniques in clinical and non-clinical areas, for example by Kim 53  and Vik et al 
90 , however these studies were carried out in a community setting rather than a primary 
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health care clinic. Not only does this study help in answering the question about which 
technique is most feasible in a primary care based memory clinic setting, but it also 
provides several outcomes that may be useful for future studies. For example, the 
standard deviation of the outcome measures (e.g. adherence rates, time taken, etc.) would 
help in estimating sample size. Moreover, this study also provides an insight into some of 
the issues related to participant recruitment and willingness of clinicians to recruit 
participants, for instance, irritable patients could not be recruited based on clinician’s 
discretion.   
3.4.8. Limitations 
This study has several limitations that need to be considered before interpreting its 
results. The main limitation is the small sample size, which likely explains why most of 
the demographic variables were not correlated with adherence rates. For example, 
previous studies have found a correlation between patient variables such as gender, living 
situation, and race, and medication non-adherence. Such variables did not achieve a 
statistically significant correlation in our present study.  
Secondly, the correlation between the adherence tools may be biased as a result of 
the absence of clear cutoff definition for adherence. Most adherence studies in the 
literature have agreed upon 80% as the cutoff to define adherent versus non-adherent. 
3,17,41  However, a previously published study has suggested that 90% adherence serves as 
a cutoff of 5 mg Donepezil. 13  This cutoff was determined with the help of 
pharmacokinetic and pharmacodynamic study of Donepezil. 13  Such considerations were 
not taken into account for the present study.  
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Thirdly, the validity of statistical tests is another limitation of the present study 
because it fails to provide statistically significant results. For example, statistical tests 
such kappa coefficient fail in a case when the value of one of the boxes in the 2x2 table 
drops below five. 
Finally, the sample frame chosen in this cross-sectional study was small which 
questions the generalizability of the results to the entire memory clinic population. In this 
case, irritable patients along with some others could not be approached in the study. 
These patients may have unique characteristics that could have an effect on their 
adherence, which could not be determined. Despite of these limitations, the study design 
was useful in providing descriptive adherence data in an otherwise unexplored clinical 
setting.  
3.5. Conclusion and future direction 
Clinicians continue to face a dilemma of determining how well patients adhere to 
their medications. This study pointed out that MPR was more feasible than pill count, 
however, it cannot be concluded that one is better than the other. As several techniques 
are available to measure adherence, there is a lack of agreement between most indirect 
techniques. This study showed that there was no correlation or agreement between the 
scores measured by pill count and MPR. The reason for this could be that these 
techniques measure different aspects of adherence rather than just medication 
consumption. Perhaps the best approach for assessing medication adherence is to 
triangulate at least two adherence assessment methods. In absence of either MPR or pill 
count, one may consider the use of self-report measures on caregivers to ascertain 
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medication adherence. Future research could usefully explore the utility of the self-report 
measure in a memory clinic setting.  
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CHAPTER 4: OVERALL DISCUSSION AND CONCLUSION 
 
As the population of Canada ages rapidly, it will face an increasing number of 
comorbities, resulting in an increased number of personal medications. As shown in the 
results from the memory clinic study, the number of medications did indeed increase with 
the number of co-morbidities. With the ever-expanding aging population, the prevalence 
of dementia and Alzheimer’s disease will continue to rise. At present, as there is no cure 
for these diseases, the current therapy relies on managing the condition and slowing down 
the progression of the disease using the non-curative drugs that are available. An 
important factor that will determine the success of slowing the progression of these 
diseases and their impact is optimum adherence to medication. However, factors such as 
memory impairment make it more difficult for older adults to manage their medications, 
setting up a vicious cycle of reducing adherence to necessary medication. 
To help address these issues, the memory clinic model is well placed to address a 
number of interrelated issues of cognitive impairment including reduced medication 
adherence. Although memory clinics have already incorporated attention to adherence as 
part of their practice in dealing with cognitively-impaired older adults, clinicians still face 
the dilemma of choosing an accurate adherence method. It is the pharmacist in the 
memory clinic setting that is assigned to perform the adherence check on patients. He/she 
is well placed to consider this problem. This thesis has examined the issues around 
addressing the overall challenge through measurements that are part of the pharmacist’s 
skillset. 
Adherence is usually measured using pill count and/or pharmacy refill data. From the 
results of the memory clinic study, it was found that MPR was a more feasible method in 
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comparison to pill count. Pill count was infeasible as the patients that may have been seen 
previously were advised to use blister packs to improve adherence. This infeasibility of 
conducting pill count was attributed to patients either bringing a new blister pack instead 
of an unused pack or presenting with the blister pack label indicating the list of 
medications that were currently being blister packed. It was also infeasible as many 
patients forgot to bring their pill bottles to the clinic. In the study, we concluded that there 
is no correlation between adherence scores measured by pharmacy refill data and pill 
count which indicates that the best overall approach is to triangulate two or more 
adherence-assessing methods to measure medication adherence. Nevertheless, and 
although MPR was more feasible than pill count, it is advisable to still use both methods 
to ascertain medication adherence as MPR and pill count may assess different aspects of 
the medication-taking behaviour.  
In cases where the pill count is not feasible, other indirect methods such as self-
reports or semi-structured interviews may be used. For example, the Morisky scale is a 
simple to use and validated questionnaire intended to assess adherence by asking four 
questions. Use of self-reports may be questionable in the current setting as patients are 
presented with memory concerns, however the pharmacist may use this tool on caregivers 
instead. Literature reviews on this topic have again supported the suggestion of 
triangulation of data from another adherence assessment technique in addition to a self-
report measure.27,28,41  
The ultimate prevalence of non-adherence in this population still remains unclear. 
The scoping review (Chapter 2) found that non-adherence had a wide range in the current 
population. This was also the finding in a meta-analysis that investigated older adults 
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regardless of any medical conditions.15 The memory clinic study (Chapter 3) also 
witnessed a disparity between the number of non-adherent patients identified using MPR 
and pill count. As addressed in Chapter 2, a commonly-cited reason for this wide range of 
prevalence of non-adherence has been due to a lack of a consistent ‘gold’ standard. 
Furthermore, it still remains unclear from the literature, as well as perspectives gained in 
the scoping review of Chapter 2 as well as the memory clinic study of Chapter 3 as to 
what proportion of adherence can be considered optimal. 
For the purpose of defining adherence, this dissertation used a value of 80% as a 
cut-off to distinguish adherent patients from non-adherent. This seems justifiable, as most 
research on medication adherence across different older adult populations has regarded 
80% as satisfactory compliance since the 1960s.7,12,27, However, a pilot study conducted 
in 2010 using pharmacokinetic and pharmacodynamic parameters determined that 90% 
adherence was necessary for the use of 5mg Donepezil in order to maintain a full 
therapeutic coverage of the drug.13 The quantitative assessment of adherence with the 
help of PK/PD model is referred to as ‘Pharmionics’.41 At this point, not many studies 
have investigated PK/PD parameters to establish a cutoff for adherence rates and the data 
remain sparse.  
Absence of any gold standard along with an arbitrary adherence cut-off also 
hinders the ability to identify the predictors of non-adherence. From Chapter 2, it was 
seen that cognitive impairment along with increased caregiver stress were key barriers to 
adherence in cognitively impaired older adults. Although the approach taken in Chapter 3 
(with the sample size that was feasible) was not successful in finding statistically 
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significant correlations between patient variables and non-adherence, the results did find 
a similar pattern as what has been accepted in the literature.  
The memory clinic study described in Chapter 3 showed that caregivers used 
adherence aids such as blister packs, weekly pillboxes and miscellaneous techniques. 
Although the study could not find significant differences between adherence rates 
according to different adherence interventions, it was still interesting to know what kind 
of interventions are being used in the memory clinic population. In the literature reviewed 
in Chapter 2, it was found that interventions such as transdermal patches and once-daily 
higher doses received significant caregiver satisfaction. These interventions, however, 
were not found to be in use in the current practice. Several reasons could explain this, for 
example, transdermal alternatives are not available for many of the oral chronic 
medications that a patient might be on within the study population. Further, once-daily 
higher dose cannot be implemented for all drug classes. Nevertheless, adherence aids 
such as blister packs and weekly pillboxes have been studied and have been implemented 
in practice with great success. One particular disadvantage that could hamper the use of 
weekly pillbox is that it may be difficult to use for patients with cognitive impairment. 
However, it was found that all the patients in the memory clinic who used this 
intervention were adherent. This adherence pattern could possibly be due to caregiver 
support.  
 In conclusion, this thesis explored different aspects of medication adherence in an 
otherwise uncharted area. The work presented in this thesis showed that knowing the 
most feasible instrument does not guarantee an accurate assessment of non-adherence and 
that this area of research still remains of significant importance. 
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Appendix 1: Search strategies for literature review 
 
DATABASE: PUBMED 
 
SEARCH DATE: 1966 – December 3, 2014 
 
KEYWORDS("medication adherence" OR "Medication Adherence"[Mesh] OR 
"Medication Non-Adherence" OR "Medication Non Adherence" OR "Medication 
Nonadherence" OR "Medication Compliance" OR "Medication Non-Compliance” OR 
"Medication Non Compliance" OR "Medication Noncompliance" OR "Medication 
Persistence" OR "drug adherence") AND (dementia OR Alzheimer OR alzheimer’s 
disease OR "lewy body" OR “lewy bodies” OR “cognitive impairment”) AND (assess* 
OR measur* OR evaluat*) 
 
RESULTS: 90 articles 
 
FILTERS: No filters activated 
 
COMMENTS: Dr. Fernandez and I went through titles/abstracts and agreed on articles 
that looked like they had potential for the scoping review. Collectively agreed on 45 (2 
Spanish and 1 Japanese) articles that were relevant to the project and it decided to include 
these in the literature review.  
 
 
DATABASE: EMBASE 
SEARCH DATE: 1974 to January 24, 2015 
 
KEYWORDS(medication adherence OR medication non-adherence OR medication 
non Adherence OR medication nonadherence OR medication compliance OR medication 
non-compliance OR medication non compliance OR medication noncompliance OR 
medication persistence OR drug adherence) AND (dementia OR Alzheimer OR 
alzheimer disease OR lewy body OR lewy bodies OR cognitive impairment) AND 
(assess* OR measur* OR evaluat*) 
 
RESULTS: 174 articles 
 
FILTERS: No filters activated 
 
COMMENTS: 45 (1 Spanish) relevant articles were identified out of which, 23 articles 
were previously identified in PUBMED search. 
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DATABASE: CINAHL 
 
SEARCH DATE: 1996- January 24, 2015 
KEYWORDS(medication adherence OR medication non-adherence OR medication 
non Adherence OR medication nonadherence OR medication compliance OR medication 
non-compliance OR medication non compliance OR medication noncompliance OR 
medication persistence OR drug adherence) AND (dementia OR Alzheimer OR 
alzheimer disease OR lewy body OR lewy bodies OR cognitive impairment) AND 
(assess* OR measur* OR evaluat*) 
 
RESULTS: 65 articles 
FILTERS: No filters activated. 
 
COMMENT: 18 articles were found relevant to the research question, out of which 9 
articles were previously identified in PUBMED and EMBASE databases. 
 
 
DATABASE: PSYCINFO 
 
SEARCH DATE: January 24, 2015 
KEYWORDSmedication adherence OR medication compliance OR medication 
persistence OR medication nonadherence OR medication noncompliance OR medication 
non-persistence OR drug adherence OR drug compliance OR drug persistence OR patient 
compliance OR patient adherence AND (dementia OR Alzheimer OR alzheimer disease 
OR cognitive impairment) 
 
RESULTS: 4 Articles 
 
COMMENT: 3 articles were identified as relevant. 2 articles were previously identified 
in the previous databases.  
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Appendix 7: Information letter and consent form (Severely impaired participants) 
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Appendix 8: Feedback Letter 
 
